








This thesis has been completely composed by myself. The experimental work
contained within this thesis was completed in September 1996.
The work contained within it has either been performed entirely by myself or by
myself as a member of a research group. That part performed by the research group,
and those areas in which I have received assistance, I should like to acknowledge
below.
I have not submitted this thesis in candidature for any other degree, diploma or any
other professional qualification.
Signed. Paul David Waterworth.
Acknowledgements
I should like to thank Mr John Wallwork FRCS (Medical Director of Papworth
Hospital and Director of Imutran Ltd.) for giving me the opportunity to spend time
working in this exciting field of research.
I should like to thank Dr David White PhD (Director of Imutran Ltd.) and Mr John
Wallwork FRCS, in their capacity as directors of this research programme, for the
assistance and guidance which I have received. In addition, I should like to thank Dr
David White for acting as my personal supervisor and reviewing this thesis.
I should like to thank Professor Keith James PhD, DSc FRSE (Professor of
Immunology, University of Edinburgh Medical School) for acting as my Edinburgh
University supervisor and for so thoroughly reading the first draft of this thesis and
suggesting some valuable amendments.
I should like to thank Mr John Dunning FRCS (Consultant Surgeon, Papworth
Hospital), Mr Peter Braidley FRCS (Specialist Registrar, Papworth Hospital) and
Mr Michael Tolan FRCS (Research Fellow, Imutran Ltd.) for their assistance with
surgical procedures.
I should like to thank Dr Emanuelle Cozzi MD (Imutran Ltd.) for his guidance with
construction of the immunosuppressive strategies and for his assistance with the
performance of the total haemolytic red blood cell anti-pig antibody levels.
I should like to thank Dr Gillian Langford PhD (Imutran Ltd.) for analysing ear
clippings from transgenic pigs for the degree of human decay accelerating factor
expression.
2
I should like to thank Dr Richard Warner PhD (Imutran Ltd.) for his advice and
assistance with the performance of the anti-galactose alpha 1-3 galactose antibody
levels.
I should like to thank Dr Gilda Chavez MD (Pathologist, Imutran Ltd.) for help with
the production and analysis of histological data.
I should like to thank Richard Lancaster (Imutran Ltd) for the production of the hDAF
transgenic pigs.
I should like to thank Dr Spiegelholter PhD (Statistician, MRC Department of
Statistics, Addenbookes Hospital) for his advice with statistical analyses.
Finally, I should like to thank Imutran Ltd who provided the hDAF transgenic pigs
and the funding for this research project.
3
Abstract
Clinical transplantation is an effective form of treatment for end stage organ disease.
Transplantation is restricted by the number of available donor organs and this has lead
to an enthusiasm for xenotransplantation. The pig has many anatomical and
physiological similarities to man and is therefore the most likely donor. When organs
are transplanted between species of wide phylogenetic disparity, such as pig and
human, they undergo a rapid and aggressive rejection process known as hyperacute
rejection (HAR), which is due to preformed natural antibody activating the
complement cascade resulting in endothelial cell damage. Complement activation may
be inhibited by human decay accelerating factor (hDAF) which is a species specific
complement regulator. Pigs transgenic for hDAF were created by microinjection of
human DNA into fertilized pig oocytes. Ten control hearts, eight heterozygous hDAF
transgenic hearts and one homozygous hDAF transgenic heart, were transplanted
heterotopically into the abdomen of non-immunosuppressed cynomolgus monkeys.
The heterozygous hDAF transgenic pig hearts had a median beating time of 123 hours
(range 97-126 hours) and the control pigs hearts had a median beating time of 39
hours (range 0.4 -104 hours {p<0.0001}). The single homozygous hDAF transgenic
pig heart had a beating time of 132 hours. The control group demonstrated a bimodal
distribution of survival with five hearts having a median beating time of 0.96 hours
(range 0.4-8 hours) and five hearts having a median beating time of 78 hours (range
69-104 hours). None of the transgenic grafts were hyperacutely rejected, all being lost
due to acute vascular rejection (AVR). Half of the control grafts were hyperacutely
rejected and half failed due to AVR. So it would appear that the hDAF transgene
protects the xenograft against HAR but other factors may also be playing a part as
suggested by the surprisingly long survival of half of the control grafts. The level of
preformed total anti-pig antibodies (APAb) and anti-galactose alpha 1-3 galactose
(AAG) IgM antibodies may also influence graft function and the presence of hDAF on
the graft may confer some degree of protection against the elicited total APAb and
elicited AAG IgM antibody mediated AVR. In addition, graft antigenicity, as measured
by the amount of glycosylated sugar epitopes, is also likely to be important.
Fifteen heterozygous transgenic and five control hearts were then transplanted
heterotopically into the abdomen of immunosuppressed cynomolgus monkeys. Of the
transgenic hearts ten were immunosuppressed with a high cyclophosphamide (CyP)
regimen (group 1) and five were immunosuppressed with a low CyP regimen (group
2). All control hearts were immunosuppressed with the high CyP regimen. The hDAF
transgenic hearts in the high CyP group had a median beating time of 40 days (range
6-62 days) compared with 9 days (range 8-34 days) for those in the low CyP group.
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This difference was statistically significant (p <0.05). The control grafts had a median
beating time of 55 minutes (range 2-180 minutes). The difference between the control
grafts and the high CyP transgenics was statistically highly significant (p <0.001). The
difference between the control grafts and the low CyP transgenics was also statistically
significant (p <0.05). All control hearts were hyperacutely rejected. Only two hearts in
the high CyP group were lost due to AVR, on days 6 and 62: all other hearts showed
no evidence of rejection. All hDAF transgenic hearts in the low CyP group underwent
AVR. These results confirm that HAR can be abrogated with the hDAF transgene in
this pig-to-primate model and that prolonged survival can be achieved. Perioperative
CyP would appear to be an essential component of this regimen, without which, graft
loss due to antibody-mediated AVR is encountered.
Finally, hDAF transgenic pig hearts were transplanted both heterotopically, and
orthotopically into immunosuppressed baboons. No graft underwent F1AR and
survival of heterotopic pig-to-baboon heart xenografts for up to 21 days was achieved.
Survival of life-supporting hDAF transgenic pig hearts for up to nine days was
achieved when immunosuppressed with CyA, CyP and steroids, and no other immune
modulating strategies, and histological analysis of this graft showed normal
myocardial architecture with no evidence of rejection.
We anticipate that with the advent of new immunosuppressive agents specifically
targeting the anti-xenograft antibody response, improved survival of hDAF transgenic
pig organs in primates will be achieved and that clinical xenotransplantation with
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The need for xenotransplantation
Clinical transplantation has become a victim of its own success. It is an effective form
of treatment for end stage organ disease not amenable to more conservative therapy.
Recipients enjoy prolonged survival, improvement in their quality of life1 and the cost
benefit for society2,3 is such that an increasing number of patients are being referred for
transplantation. The donor pool, however, has not expanded to keep pace with the
rising recipient demand and the gap between the number of patients requiring
transplantation and those receiving them has steadily increased.
What, therefore, can be done to improve the situation? The essential limiting factor is
the number of cases of confirmed brain stem death. Currently, in the United Kingdom,
this figure is approximately 1200-1350 cases per year. Of these, approximately 20%
will have a medical contraindication to organ donation and, of the remainder, consent
to organ donation will not be given in 35%. Thus, the maximum number of potential
organ donors is 650-700 a year. It has been shown that even if organs were removed
from all potential donors, demand would continue to outstrip supply.4
Living donors have been a source of kidneys for many years and currently represent
around 4-5% of renal transplants in the United Kingdom. More recently, living related
segmental liver and lung transplants have been performed. However, the use of living
related donors conflicts with the ethical principle of 'primum non nocere'- first do no
harm, as there is clearly a significant risk to such donors.
This short fall in donor organs has lead to an enthusiasm for xenotransplantation. The
possibility of using animals as donors is attractive for a number of reasons.
• Ready availability of organs would even out the discrepancy between demand and
supply.
• Increased availability of organs would mean that the current indications for
transplantation could be reassessed.
• Problems of storage and ischaemic damage to organs could be minimized.
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• Transplants could be planned more efficiently in line with routine work.
• Potential exists for donor organ and recipient pre-treatment to allow specific
modulation of the immune response.
The barriers to xenotransplantation
Concordant and discordant xenotransplantation
Xenotransplantation can be divided into concordant and discordant depending on the
phylogenetic gap between the donor and recipient species.5 Transplants between
concordant species (e.g. chimpanzee-to-man) are rejected over a period of days in a
manner analogous to first-set allograft rejection. Whereas grafts between discordant
species (e.g. pig-to-man) are rejected in minutes to hours. The rapid rejection of
discordant xenografts is known as hyperacute rejection (HAR) and is due to preformed
natural antibody activating the complement cascade resulting in endothelial cell damage
and lysis. Clearly, for purely immunological reasons it would be easier to use a
concordant species as a donor for organ transplantation into man and yet there are
many objections to the use of primates for organ donation (vide infra).
The pig as a potential donor
Although primates offer potential concordant combinations with man, there are a
number of disadvantages in the use of primates. Chimpanzees6 and other apes are
endangered species and apes share many of our behavioural characteristics, making
their use ethically and socially less acceptable.7'8 Other monkeys, not as closely related
to man, such as baboons, are plentiful but reach a maximum size (20-30 kg) yielding a
heart which is too small to support an adult human circulation. It is possible that
organs from baboons could be used for paediatric heart transplantation as has already
been performed without success.9 However, ethical issues and low breeding capacity
make their widespread use unlikely.
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It is likely therefore, that any successful large scale xenotransplantation programme
will use a non-primate species, such as the pig. The pig is generally accepted as the
most likely candidate.10 It has many anatomical and physiological similarities to
man.11,12 Perhaps the most important potential barrier to successful xenotransplantation
is that some types of organs from disparate species may not function adequately in a
new environment. This issue is particularly difficult to evaluate, especially in humans,
because so few xenotransplants have survived for prolonged periods. It is likely that
some physiological functions of xenogeneic organs will remain intact but others will
not. While it seems reasonable to expect that appropriately sized hearts may function
adequately in widely disparate species combinations it has been suggested that the
situation might not be quite so simple. The porcine heart is essentially suspended in the
thoracic cavity by its major blood vessels, with its anterior surface resting near to the
sternum, and the majority of the posterior surface adjacent to the diaphragm. The
human heart, in contrast, has a trapezoidal silhouette, with a markedly eccentric apex,
which is formed by only the left ventricular mass.13 These facts may have implications
for the positioning of the cardiac xenograft within the thoracic cavity during
transplantation. They may also affect the postoperative performance of the transplanted
heart, in that it would need to adapt rapidly to the influence of gravitational changes on
blood pressure required by the human body. The problem of adaptation of the
transplanted pig cardiac xenograft to differing venous and arterial pressures within the
human body is unknown, and it is not likely to become known until clinical trials are
performed.
It has been shown by our group14 that primates surviving with pig kidney transplants
develop marked anaemia, raising the possibility that pig erythropoietin may not
function properly in primates.
It is also reasonable to suspect that significant deficiencies may exist if metabolically
more complex organs, such as the liver, are used for transplantation. Will pig proteins,
enzymes and hormones carry out their tasks in humans?15
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We know that human recipients of baboon livers have had lower levels of serum
cholesterol (consistent with levels in baboons) and remarkably low levels of serum
uric acid (since the baboon liver does not produce uric acid as the human liver does).
We already have clinical evidence that ex vivo perfusion of pig livers by blood from
human patients in fulminant hepatic failure can lead to some improvement in cerebral
activity, and therefore at least temporary support by a pig liver is likely to be
beneficial.16 And so the physiological disparity between pig and human organs may
indeed prove to be a significant barrier to clinical xenotransplantation.
Unlike monkeys, the pig is plentiful, there being over 50 million in the United
Kingdom alone. They are relatively disease free compared to monkeys whose potential
zoonoses include tuberculosis and the simian immunodeficiency virus. Pigs multiply
rapidly, having litters of more than ten, have a gestation period of 113 days, and
achieve reproductive maturity at six months. This would allow the rapid expansion to
numbers capable of supplying the demand for organs. The pig grows rapidly to a size
capable of supplying organs for even the largest human. Finally, since the pig already
forms part of the human food chain ethical objections to its use to save lives is limited.
Animal rights groups continue to object to the genetic manipulation of pigs specifically
bred for transplantation purposes and this barrier would need to be overcome prior to
the onset of clinical xenotransplantation. However, pig heart valves have been utilised
for many years and porcine insulin is used in millions of diabetics worldwide and so it
is unlikely that any ethical issues would be insurmountable.
Given that the immunological barriers may indeed be overcome there is still
considerable concern about the spread of disease from animal organs to man i.e.
xenozoonosis. A large number of pathogens have been recognised that reside primarily
in animals but can infect humans. In general these are the least worrisome potential
pathogens, since if the organisms are known, potential animal donors can be screened
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to avoid their presence. Despite the presence of many potential pathogens among
different donor species, there will almost certainly be less transmission of known
infections by xenotransplantation than by allotransplantation. This is simply because
there is much more time available to screen animals and to raise them in relative
isolation in comparison to the short time available to screen potential cadaver human
donors prior to transplantation. It is the risk from unknown potential pathogens which
poses the important infectious barrier to xenotransplantation. This issue was
highlighted by the discovery that porcine endogenous retroviruses (PERVs) may be
able to infect human cells in culture.17 However, it still remains to be proven whether
these viruses could actually infect humans and whether such infection could lead to
transmission to other individuals or to disease. Thus far, no evidence has emerged that
these agents can infect humans. So the debate about the infectious risks of
xenotransplantation are not about the risk-benefit calculations for the patient receiving
the transplant but about the risk for society as a whole. Since xenotransplantation
provides no significant benefit to non-recipients of the transplant, even a small risk of
a serious threat to public health becomes a reasonable concern.
Hyperacute rejection
When organs are transplanted between species of wide phylogenetic disparity, such as
pig and human, they undergo a rapid and aggressive rejection process known as
hyperacute rejection (HAR).18 This leads to the loss of vascular integrity and organ
function within minutes to hours.
The key features of HAR are severe endothelial cell injury, oedema, interstitial
haemorrhage and platelet thrombi leading to patchy infarction.19 The interstitial
haemorrhage and oedema seen on microscopy represent disruption of the endothelial
barrier, allowing the exudation of fluid and red blood cells.
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a) The role of antibody
The circulating antispecies antibodies20,21,22 directed against xenogeneic tissues are
independent of any sensitizing event and are termed 'preformed' or naturally occurring
antibodies.23 They are present in the blood of all immunocompetent humans. Their
origin and physiological role is unclear. They are predominantly IgM24 but preformed
antispecies IgG is also present. These antibodies predominantly recognise galactose
a 1-3 galactose (gal a 1-3 gal),25 a sugar present on the surface of some pathogens
and which is also synthesized by lower mammals,26 but not by humans and some
other primates. Binding of xenoreactive antibodies to gal a 1-3 gal on the cell surface
oligosaccharides of endothelial cells lining pig blood vessels causes activation of the
complement cascade and so triggers hyperacute rejection.
Evidence for the role of natural antibody in hyperacute xenograft rejection is provided
by the observation that depletion of these antibodies, either by plasmapheresis27 or
immunoabsorption,28 prolongs xenograft survival. Interestingly, new born baboon
serum lacks natural anti-pig xenoantibody29 and hyperacute rejection does not occur in
the pig-to-newborn baboon combination.30
The tissue distribution of the gal a 1-3 gal epitope has been studied using the IB4
lectin. This naturally occurring plant product binds specifically to galactose molecules
in the 1-3 configuration. This technique has shown dense staining on almost all
pigtissues and in particular, dense staining on pig endothelial cells.
b) The role of complement
The complement system consists of a group of 30 or more proteins accounting for
10% of the total serum protein. In general, the system functions as a cascade in a way
analogous to the clotting cascade. The complement system is important in antibacterial
defences, clearance of immune complexes and hypersensitivity reactions. The system
consists of two activation arms (classical and alternative) and a single effector arm
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(figure 1.1), the junction of which is the conversion of C3 to its active components by
the enzyme C3/C5 convertase. This enzyme exists in two isoforms, one of which is
generated by the interaction of antibody and antigen (the classical pathway) and one of
which is generated by an antibody independent mechanism (the alternative pathway).
The final result is the assembly of a complex macromolecule comprising several
complement components, known as the membrane attack complex (MAC). MAC
inserts itself into the cell membrane, creating a pore which allows free entry of solutes
and the death of the cell.31,32'33
The alternative pathway is activated by a variety of molecules and surfaces. This is
controlled by molecules which exist both on the surface of mammalian cells and in the
soluble phase.34,35 In the classical and alternative pathways C3 convertases also act to
activate C5, a component of the lytic pathway, and are therefore known as C3/C5
convertases.
In addition to the direct damage by the lytic pathway, complement components such as
C3a released into the soluble phase act as powerful chemoattractants for neutrophils.




Figure 1.1. The complement cascade.
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Because the complement cascade is an amplifying cascade, a series of membrane-
bound and serum factors are present to protect the hosts tissues from destruction by
their own complement. These factors are species specific36 and known as complement
regulatory proteins (CRPs) or regulators of complement activity(RCAs).37 These
RCAs include decay accelerating factor or CD55 (DAF),38 membrane cofactor protein
or CD46 (MCP)39 and protectin or CD59.40
Evidence for the role of complement in hyperacute xenograft rejection comes from the
observations that:
• serum complement levels fall on revascularization of a graft that rejects
hyperacutely
• complement components accumulate in rejecting xenografts41
• depletion of recipient complement, by cobra venom factor (CVF)42 or soluble
complement receptor 1 (SCR1),43 results in prolonged xenograft survival.
c) The role of endothelial cell activation
Normal "resting" endothelial cells promote a local anticoagulant environment
preventing adhesion of neutrophils or platelets and the generation of thrombin. The
endothelium also prevents the egress of blood constituents into the interstitium. It has
been shown that the binding of xenoreactive natural antibody to gal a 1-3 gal residues
on donor endothelial cell glycoproteins results in activation of the complement cascade
by the classical pathway and simultaneous endothelial cell activation.44 Once
"activated" endothelial cells express a range of molecules on their cell surfaces which
are capable of interacting with white cells thus bringing about the specific events of
neutrophil adhesion and diapedesis.45
Endothelial cells are important in xenotransplantation for several reasons. Firstly, since
they line the blood vessels of the donor organ they are the first cell type exposed to
attack by the immune system of the recipient species. The early events comprise
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endothelial cell retraction, the translocation of the adhesion molecule P selectin to the
cell surface, and the production of platelet activating factor. Later events such as the
expression of E selectin on the cell surface require synthesis of the protein de novo and
occur within hours rather than minutes.
Endothelial cell activation can promote HAR by three mechanisms.46 Firstly,
endothelial cells retract from one another leading to interstitial haemorrhage and
formation of extracellular oedema. Secondly, the expression of P selectin leads to
neutrophil adherence. Thirdly, activated endothelial cells become prothrombotic.
d) The role of clotting and platelets
The presence of platelet thrombi has been one of the cardinal features noted in
histology of hyperacutely rejected organs. This has lead to the hypothesis that platelet
thrombi associated with fibrin may be a final pathway of tissue damage in HAR.
The coagulation cascade has many analogies with the complement system. It has two
potential activation arms with a common effector arm and consists of a cascade of pro¬
enzymes, many of them serine proteases. Furthermore, complement activation
promotes the coagulation cascade. Coagulation may be initiated by the "intrinsic"
pathway which is activated as a result of the interaction of factor XII with foreign
surfaces. Activated factor Xlla then feeds down the pathway via factors XI, IX
and X. Factor Xa is part of the common effector pathway and leads to the conversion
of prothrombin to thrombin, which in turn converts fibrinogen to fibrin. The fibrin clot
is stabilised by Factor XIII. Factor Xa can also be activated by the action of Factor
Vila in conjunction with tissue factor via the "extrinsic" pathway.
The formation of platelet thrombi is an equally complex process. The initial binding of
platelets to the endothelium is dependent upon the interaction between platelets and
Von Willebrand's Factor (VWF) on the endothelium. Following platelet activation
which is promoted by thrombin, the platelets express P selectin on their surface.
Interaction with fibrinogen and VWF leads to platelet aggregation and adherence to the
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endothelium. There are several theoretical mechanisms by which xenografts might
activate coagulation and platelet thrombi. Tissue factor is expressed abundantly on the
subendothelial matrix. Thus, endothelial cell retraction, which is part of their
activation, exposes tissue factor and might promote coagulation by the extrinsic
pathway. Furthermore, the normal function of endothelium as an inhibitor of the
coagulation cascade, may be disturbed in HAR.47
Even if hyperacute is overcome it is likely that acute vascular rejection and chronic
cellular rejection will pose significant barriers to successful clinical
xenotransplantation.
Most studies in large animal species have indicated that mechanisms of cell-mediated
immunity to discordant xenografts are fundamentally similar to those involved in
allograft rejection but stronger. The strength of the cellular immune responses to
discordant xenografts will probably be so strong that it is unlikely that it will be
controlled by the types of non-specific immunosuppression used routinely to prevent
allograft rejection. Indeed, it may even be necessary to induce specific immunological
tolerance to some of the most antigenic xenogeneic molecules in order for
xenotransplantation to become a clinical reality.
The abrogation of hyperacute rejection
The rapid destruction of discordant xenografts by HAR has made the prevention of
this response a priority. Until this process has been overcome the elucidation and
manipulation of further immune responses cannot be addressed. Strategies aimed at
preventing HAR have taken one of two forms: either complement depletion and
inhibition or antibody depletion.
Complement inhibition may be achieved with either fluid-phase complement inhibitors
or with membrane-associated complement regulators of the recipient species that are
expressed on the xenogeneic target cells. Examples of the former include cobra venom
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factor (CVF)48 and recombinant soluble human C receptor 1 (sCRl).43 Cobra venom
contains, in addition to many toxins and enzymes, a C3b-like molecule, CVF, that is
resistant to human inactivating factors. This C3b analogue combines with components
of the alternative pathway of complement, forming a highly stable enzyme complex
that causes massive consumption of C3, Factor B, and members of the memrane attack
complex, resulting in exhaustion of the complement cascade. SCRl is a truncated
recombinant form of the naturally occurring human protein CR1 (CD35, C3b/C4b
receptor), which inhibits both the classical and alternative complement pathways by
binding to proteins (C3b and C4b) of the multi-subunit C3 and C5 convertases and
promoting the dissociation of the catalytic subunits (C2a and Bb).
Membrane associated complement regulating proteins (CRPs) such as decay
accelerating factor (DAF), membrane cofactor protein (MCP) and CD59 have become
the objects of great attention in the field of xenotransplantation.
Human decay accelerating factor (hDAF), also known as CD 55, is a 70 kiloDalton
protein.49 The active portion of the molecule is joined to a glycosyl
phosphatidylinositol (GPI) anchor which is embedded in the cell membrane. This
anchor may allow the DAF molecule to move in the plane of the membrane. In
addition, because of the highly lipid soluble nature of the tail, DAF can move from the
soluble phase to insert itself into the lipid membrane. DAF is present on many cells
including all circulating cells and endothelial cells. A form of DAF lacking the GPI tail,
exists in soluble form in plasma.
DAF works by promoting the dissociation of both the classical and alternative pathway
C3/C5 convertases (figure 1.2). Thus, DAF prevents the amplification of the
complement cascade associated with the binding of C3b to the human cell.
DAF from any species is an efficient inhibitor only of complement from its own
species. This property is termed "species restriction" and has important implications
for xenotransplantation. It has been demonstrated that human DAF is an inefficient
inhibitor of pig complement.36 It is also reasonable to assume that pig DAF is an
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inefficient inhibitor of human complement. Thus, a pig organ transplanted into a
human is vulnerable to damage by human complement as it lacks effective protection
mechanisms against human complement.
Human decay accelerating factor (hDAF) has been purified and it has been
demonstrated that it can be taken up into the membrane of red blood cells and then
prevent the assembly of C3 and C5 convertases.50
The transfer of molecules such as hDAF to cells of other species may be achieved in a
number of ways. Firstly, because of its highly lipid soluble GPI tail, DAF in the
serum will spontaneously insert into cell membranes.51,52 This process has become
known as "painting". Thus, if a significant amount of hDAF can be produced in the
serum, it is passively adsorbed onto cells. Secondly, the target cell can be induced to
produce the foreign protein by insertion of human DNA into the cell. On a tissue
culture basis this is most simply achieved by linking the human DNA to a
"transfecting" virus such as an adenovirus which regularly inserts itself into the host
genome.53'54 However, such transfection is applicable only to cells in culture. The
creation of a transgenic animal requires microinjection of DNA into the cell
(figure 1.3) at the single cell stage. Mice transgenic for human CD59 have been
developed and shown to have biological activity, demonstrated by decreased MAC
formation, when perfused ex-vivo with human blood.55 Pigs transgenic for hDAF
have been developed by our group in Cambridge56,57 (see later) and pigs trangenic for
hCD59 have also been produced.58 Of the many complement regulator proteins hDAF
was chosen as the initial transgene for investigation as hDAF acts early in the
complement cascade and therefore is likely to be the most powerful complement
regulator.
Ex-vivo perfusion of hDAF transgenic pig hearts with human blood59 and ex-vivo
perfusion of hCD59 transgenic pig hearts with human blood60 demonstrated protection
of pig hearts against hyperacute rejection in both studies. Hearts fron transgenic pigs,
expressing hCD59 and hDAF on the cell membranes of erythrocytes, have been
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transplanted heterotopically into baboons. The grafts survived for up to 30 hours
compared with control pig hearts which survived for only 90 minutes.61 This strategy
relied on the "painting" of vascular endothelium with hDAF as blood flows past.
In the struggle to overcome hyperacute rejection other groups have concentrated on the
elimination of preformed natural antibodies against the carbohydrate epitope galactose
a 1-3 galactose. This epitope is present on glycolipids and glycoproteins of all
mammals up to and including New World monkeys but absent from Old World
monkeys and higher primates including humans. It is the major xenoantigen which is
recognised by naturally occurring antibody in human serum. The epitope is generated
by galactosylation of lactobiose by a 1-3 galactosyltransferase. Blockage of this
xenoantibody-xenoantigen binding can be achieved in several ways.
Plasmapheresis62,63 or plasma exchange is an accepted form of treatment in some
autoimmune conditions, and is clinically well tolerated. Several workers have shown
that antibodies to xenoantigens can be reduced by plasma exchange. There is,
however, a rebound of antibody within one to five days and the antibody titre can
exceed the pre-depletion levels. However, in addition to removing the antibodies,
plasmapheresis also removes other protiens including cytokines and complement
components.
Antibody depletion can also be achieved by immunoabsorption28 on antigen specific
columns (Staphylococcal protein A columns which bind to the Fc portion of
antibodies) and antibody blockade can be achieved by intravenous infusion of gal a 1-
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Figure 1.2. Diagram to show activation of the complement cascade, its effect and the
point of action of decay accelerating factor (DAF), membrane cofactor protein (MCP)
and CD59 (permission for reproduction from E Cozzi, Imutran, Cambridge).
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Figure 1.3. The microinjection of human DNA into a fertilized pig oocyte.
These, however, depend on partial and transient depletion of xenoantibody while
donor directed genetic approaches, which potentially offer a more permanent solution,
have been suggested such as knocking out the galactosyl transferase and suppression
of the product of the galactosyltransferase by competition.65 Murine monoclonal anti-
idiotypic antibodies directed against human anti-a gal antibodies may also prove to be
of some importance.66
Other groups have attempted the depletion of preformed natural antibody by perfusing
an organ of the donor species with the blood or plasma of the recipient. In theory, the
specific anti-xenograft antibody binds to the determinants in the graft, thereby
removing the specific antibodies which cause HAR. This can also be achieved by the
serial transplantation of organs which also produces reduction of preformed
antibodies. Unfortunately, in none of these experiments is antibody depletion complete
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nor is depletion of antibody specific. The accompanying loss of other proteins, such as
complement, makes the improved xenograft survival difficult to interpret.
There is also active research ongoing in the field of genetic engineering of endothelial
cells to ameliorate endothelial cell activation and xenograft rejection.67
The role of blood grouping in xenotransplantation
There is a close relationship of the pig gal a 1-3 gal to human ABO blood groups.
Both are carbohydrate structures expressed on the surface of cells and there are
naturally occurring antibodies to both in individuals without prior exposure to the
antigen. This raises the question of blood groups in pigs68 and their role in
xenotransplantation. Only man and apes express blood groups on both red blood cells
and endothelial cells.69,70 Lower monkeys such as baboons express ABO groups on
their endothelial cells but not their red blood cells. Pigs also have blood groups, which
have a limited analogy to human ABO groups, but pigs do not express these groups on
their endothelium. There does not seem to be any benefit in ABO matching in
xenotransplantation when pigs are used as the donor, which is not surprising since
they do not express the antigen on endothelial cells.
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Clinical Xenotransplantation
Year Organ Donor No. of Cases Survival
1964 Kidney Chimpanzee 12 <9 months
1964 Kidney Monkey 1 10 days
1964 Kidney Baboon 1 4.5 days
1964 Kidney Baboon 6 <2 months
1964 Heart Chimpanzee 1 hours
1969-73 Liver Chimpanzee 3 <14 days
1977 Heart Baboon 1 hours
1977 Heart Chimpanzee 1 4 days
1984 Heart Baboon 1 4 weeks
1992 Liver Baboon 1 70 days
1992 Heart Pig 1 24 hours
1992 Liver Pig 1 24 hours
1993 Liver Baboon 1 1 month
Table 1.1. Summary of human xenograft experience.
The clinical experience to date is summarised in table 1.1. We can see from table 1.1
that the large majority of attempts at clinical xenotransplantation have involved primate
kidneys. There have been only five attempts at clinical cardiac xenotransplantation,
four of which have involved primates, there being only one example of non-primate to
human cardiac xenotransplantation. In 1964 there were 12 chimpanzee-to-man kidney
transplantations.71 The immunosuppressive regimen included, azathioprine, steroids,
actinomycin-C and local graft irradiation. Prompt renal function, with diuresis was
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observed in all cases. Most grafts failed within two months, but one graft survived for
nine months. The grafts were lost by a process of rejection similar to that seen by
human allografts. With the same immunosuppressive regimen a further six baboon-to¬
man kidney transplantations were performed and graft survival ranged from 19 to 60
days.72 Histological analysis of the grafts demonstrated a heavy infiltration of
lymphocytes. The severity of rejection was greater than in the chimpanzee-to-man
kidneys.
The first clinical attempts at chimpanzee-to-man liver transplantation resulted in less
than 14 days graft survival.73
The first attempt at clinical cardiac xenotransplantation was in 1964, when a
chimpanzee heart was transplanted orthotopically into a patient with preterminal
shock.74 There is no record of any immunosuppressive therapy being used in this
case. The graft functioned for only two hours. The next two cardiac xenografts were
performed for the purpose of left ventricular assistance in two patients who were in
cardiogenic shock following surgery for aortic stenosis. The donors were baboon and
chimpanzee. The baboon heart maintained a moderate circulation for only six hours
and the chimpanzee heart functioned for four days. Histological analysis of these
grafts demonstrated severe rejection.75 In 1984 a baboon heart was successful in
supporting the life of a neonate for four weeks.9 In this case the patient was
immunosuppressed with cyclosporin A and steroids and histological examination of
the graft demonstrated evidence of severe rejection with a heavy cellular infiltrate of
mononuclear cells.
The most recent attempt at clinical cardiac xenotransplantation was in 1992, when an
unmodified pig heart was transplanted orthotopically into a patient. This graft
however, failed within 24 hours, but was apparently free of hyperacute rejection at
autopsy. An attempt was made to remove anti-pig antibodies from the patient by
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perfusing two pig hearts ex-vivo with his blood. The patient received conventional
immunosuppression with cyclosporin A, azathioprine and steroids.76
So to date we can see that clinical xenotransplantation, although a potential solution to
the donor organ shortage, has not been very successful.
The aim of this thesis is to investigate the abrogation of hyperacute rejection when
hDAF trangenic pig hearts are transplanted heterotopically into non-
immunosuppressed cynomolgus monkeys and to study the effect of
immunosuppressive regimens on the prolongation of cardiac xenograft survival in
this pig-to-primate model. In anticipation of clinical pig-to-human cardiac
xenotransplantation we also aim to investigate the ability of the hDAF transgenic pig
heart in supporting the life of a primate.
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Chapter Two
Abrogation of hyperacute rejection in
pig-to-cvnomolgus monkey heterotopic cardiac xenotransplantation
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Introduction
It has already been shown that hDAF protects pig hearts from hyperacute rejection
when perfused with human blood ex vivo.59 The aim of the experiments in this chapter
was to investigate the ability of hDAF transgenic pig hearts to abrogate hyperacute
rejection in vivo when transplanted heterotopically into a non-human primate.
The cynomolgus monkey was chosen as the non-human primate in which to test the
human decay accelerating factor transgene as it has been shown in vitro by Tucker et al
(personal communication) that cynomolgus complement activity is down regulated by
human DAF by 84%, baboon complement activity by 79% and rhesus monkey
complement activity by 64%. The cynomolgus monkey was thus the most appropriate
of these species in which to test hDAF transgenic organs.
The United Kingdom Home Office currently restricts the number, source and species
of primate which can be used for experimentation and this also influences the pig-to-
primate models which can be employed. Wild-caught baboons can only be used in
exceptional circumstances and captive-bred baboons are rarely commercially available.
Captive-bred cynomolgus monkeys are relatively plentiful but are generally of small
size, the larger animals being difficult to purchase.
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Materials and Methods
All experimental procedures were performed according to the Code of Practice for
Scientific Procedures in Animals from the University of Cambridge and the Guidance
on the Operation of Animals (Scientific Procedures) Act 1986, Home Office, UK.
Donor selection
Heterozygous Large white/Landrace cross-piglets were selected as donors on the basis
of the degree of hDAF expression and body mass. All animals were offspring of the
A74 founder which had been made transgenic for hDAF by microinjection of a
minigene construct (6.5kb) containing a 4kb genomic DNA fragment which
incorporates the DAF promoter, the 5'-untranslated and signal peptide sequence of the
DAF gene, the first exon and intron of the gene. This genomic DNA fragment was
linked to the cDNA fragment that coded for the remaining exons of the DAF gene.56
Ear clippings from each donor were used to measure tissue hDAF expression.
Transgenic animals for this study were identified by DNA slot blot analysis using a
random-labelled 32P human DAF cDNA probe. Expression of the transgene was
determined by Northern blot analysis, using the acid guanidium thiocyanate phenol-
chloroform extraction method, and by double determinant radio-immunoassay and
immunohistochemistry.77 The expression and distribution of hDAF in the
heterozygous animals shows great variability from organ to organ but hDAF
expression in the hearts of A74 offspring was found to be comparable with that seen in
equivalent human tissue.78
Earlier work using autopsies from 72 pigs demonstrated that the expression of hDAF
in the various tissue components of the ear clip samples correlates well with the hDAF
expression in the different organs (Personal communication Chavez et al). Vascular
endothelium, arterial smooth muscle, epithelium, hair follicle, eccrine glands, cartilage
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and soft tissues were all stained with BRIC 216 (IBGRL Research Products, Elstree,
UK), a monoclonal antibody which binds to hDAF.
Each tissue was graded from 0 to 4, according to the intensity and distribution of
staining as Grade 0 = no hDAF expression, Grade 1 = equivocal staining, Grade 2 =
irregular distribution, grade 3 = regular distribution, moderate intensity, and grade 4 =
very strong staining for hDAF, similar to or better than human controls (figure 2.5).
According to the predictive value of each parameter a score from 0 to 12 was
constructed, being achieved by the sum of the values of the endothelium (maximum =
4), arterial smooth muscle (maximum = 4) and the average of the non-vascular related
tissues i.e. epithelium, hair follicle, eccrine glands, cartilage and soft tissues
(maximum = 4). Only "top-score" transgenic donors were used i.e. those with a score
greater than 11.5 and those with a vascular endothelium score of 4. Non-transgenic
Large white/Landrace cross-piglets were used as controls.
The heterotopic abdominal pig-to-cynomolgus monkey heart transplantation model79 is
a exacting model, the technical success being hindered by the paucity of space within
the recipient abdomen and so wherever possible the smallest available piglets were
used as donors. Practically this meant that piglets of 2-4kg were used. Donor age and
sex were recorded.
Recipient selection
Healthy cynomolgus monkeys (Macaca fascicularis) with no evidence of intercurrent
infection were selected as recipients. To maximise the technical outcome monkeys
weighing greater than 2kg were selected wherever possible. Recipient age, sex and
geographical origin were also recorded.
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Donor operation
The donor pigs were sedated with ketamine hydrochloride (20mg/kg). Induction of
anaesthesia was via inhalation of a N20:02 mixture via a face mask. The thorax and
neck were prepared with antiseptic and draped. A tracheostomy was performed via a
mid-line cervical incision and a suitable endotracheal tube was inserted to allow
mechanical ventilation. Airway pressures and thoracic cage excursion were observed
to maintain good ventilation. The endotracheal tube was manipulated if necessary and
then secured in place.
Via a median sternotomy the intra-thoracic organs were exposed. The pleurae and
pericardium were opened. The heart size and morphology were inspected at this stage
and if function and morphology were not suitable the procedure would be abandoned.
Thymectomy was performed. 2-0 vicryl (soluble braided) ties were placed around the
inferior vena cava (IVC), right brachiocephalic artery and the arch of the aorta,
between the right brachiocephalic and left common carotid artery. The pig was then
systemically heparinised by injecting 2000 IU of sodium heparin directly into the
superior vena cava (SVC). This was allowed to circulate for two minutes before
proceeding. The right brachiocephalic artery was then tied and a vascular clamp was
placed around the aortic arch (just distal to the origin of the right brachiocephalic
artery) but left open until the IVC had been tied. The vascular clamp was then closed
and a 16G cannula inserted into the ascending aorta (a silastic collar was placed
5mm from the tip of the cannula to prevent it being inserted too far and so avoiding
coronary artery cannulation, tripping of the aortic valve, perforation of an aortic valve
cusp or perforation of the aortic root). The heart was then vented through the SVC and
IVC and 15ml/kg of cold St. Thomas's cardioplegic solution was gently administered
through the aortic root until cardiac activity ceased (the heart was gently compressed to
prevent distention as the cardioplegia was administered). Cold (4°C) normal saline
was then placed around the heart to aid myocardial protection. The IVC was then
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transected and the pig was allowed to exsanguinate into the thoracic cavity. The SVC
and IVC were then ligated and the whole heart-lung block was dissected free and
placed in a bowl of cold normal saline. 0-vicryl ties were placed around the left and
right hilar structures (after transecting the right upper lobe bronchus which has a
separate origin from the trachea) and the lungs were then amputated. The pulmonary
artery was transected at its bifurcation and the aorta was transected proximal to the
right brachiocephalic artery. An 0-vicryl tie was carefully secured across the roof of
the left atrium allowing all bronchopulmonary tissue to be excised (care was taken not
to occlude the coronary sinus or distort cardiac anatomy). The heart was protected in a
fresh bowl of cold saline which was mounted on a block of ice prior to implantation.
Note that the heart was kept cold at all times during the dissection.
Recipient operation
All animals were starved overnight prior to surgery. Before transfer to the operating
theatre the monkey was sedated with ketamine hydrochloride (15mg/kg) given
intramuscularly in combination with atropine sulphate (0.05mg/kg). Following
induction of anaesthesia by intravenous injection of diazepam (lmg/kg) an
endotracheal tube was inserted and the monkey was maintained on a N20:02 (1:1)
mixture, with the addition of isofluorane at a concentration of 1-2% as required. A
single dose of a prophylactic antibiotic was given (Synulox). An indwelling cannula
was inserted into a peripheral vein for administration of fluids and drugs during the
procedure. Electrocardiographic and respiratory monitoring was established.
The abdominal skin was then prepared with antiseptic solution, and sterile drapes were
applied to expose the operative field. A midline laparotomy was performed, a self-
retaining retractor was inserted and the bowel was carefully withdrawn from the
operative field and wrapped inside warm normal saline-soaked swabs. A 2-3cm long
segment of infrarenal aorta and IVC, between the inferior mesenteric vessels and the
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common iliac vessels, was isolated between silastic slings, all branches being occluded
with metal ligaclips. At this stage the donor heart was weighed and the vessels
prepared for anastomosis. 100 iu of heparin was given intravenously and allowed to
circulate for two minutes prior to occluding the IVC and abdominal aorta. The venous
anastomosis (donor pulmonary artery to recipient IVC) was performed first, followed
by the arterial anastomosis (donor ascending aorta to abdominal aorta), both
anastomoses being performed in the same way: having occluded the vessel between
the silastic slings a small longitudinal venotomy/arteriotomy was made and extended to
the appropriate size to allow end to side anastomoses.79 With the heart wrapped in a
cold swab and kept cold at all times the anastomoses were performed using 7-0
prolene sutures (monofilament) and standard microvascular surgical techniques. On
completion of the anastomoses the vessels were flushed with heparinised saline and all
air expelled. The silastic slings around the IVC were released first followed by those
around the aorta (a rapid pink flush should be seen). After checking the anastomoses
for any obvious surgical bleeding, and should none be found, the slings were carefully
removed (the ischaemic time noted) and the surgical field gently packed with swabs.
10-20mls of haemaccel was given intravenously (depending on the size of the animal).
If the heart did not spontaneously cardiovert a 2J DC shock was occasionally required
and would be repeated if necessary. If the donor heart did not return to a strong regular
beat and the monkey's abdominal aortic pressure was palpably low an intra-arterial
pressure recording was taken. The abdominal swabs were then removed, the surgical
field was carefully examined for bleeding and thorough haemostasis was achieved.
Finally, thrombin glue (Tisseal, Immuno Ltd, High Wycombe, UK) was applied
around the anastomoses and the heart and abdominal contents were carefully
repositioned to avoid compromising the activity of the donor heart.
Once the surgeon was satisfied that there was stable xenograft function and adequate
haemostasis the wound was closed with 2-0 vicryl sutures being used to close the
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rectus sheath and a 3-0 subcuticular vicryl suture to close the skin. The recipient was
allowed to recover from general anaesthesia in the most appropriate position for the




This period was critical. The animal was observed very closely during this time and
kept in the operating theatre with full anaesthetic and surgical facilities available,
should it be necessary to reopen the abdominal wound. Occasionally as the animal
recovered and tensed its abdominal muscles the donor heart position and function
would be compromised such that it became bradycardic and might stop. If such
bradycardia was detected early the abdomen was reopened and the position of the
donor heart was adjusted.
Hours 2-24
Postoperative analgesia (buprenorphine hydrochloride, 0.3mg/ml) was administered at
the discretion of the attending veterinary surgeon. During the first 24 hours the donor
heart was checked to confirm that it was beating every hour and if there was any
problem with it or with the animal the surgeon was notified.
Day 2 onwards
The general physical condition and xenograft function was checked three times each
day and any problem reported to the on-call surgeon.
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Blood sampling and monitoring
Preoperative and postoperative total anti-pig red blood cell haemolytic antibody levels
and anti-galactose a 1-3 galactose IgG and IgM levels were measured as described
below.
Method for the measurement of total anti-pig red blood cell haemolytic
antibodies
200/xl clotted monkey blood was spun at 2000rpm 4°C for 10 minutes. 50/xl of serum
was then transferred to a cryovial. This was then heat inactivated along with a 50/xl
sample of human serum for 30 minutes at 56°C. Pig blood was then prepared by
placing 2-3mls of fresh whole blood into a universal tube together with and 7mls of
complement fixation diluent ({CFD} ICN, Costa Mesa, USA). This was prepared by
adding 5 tablets of oxoid CFD with 500mls of warm distilled water. The mixture was
then centrifuged at 2000rpm for 6 minutes at 4°C three times. The supernatant was
discarded and 1ml of red cells transferred to an eppendorf tube and spun at 13000 rpm
for 2 minutes. The supernatant was again discarded and lOOyul of red blood cells
diluted with 9.9ml of CFD. Baby rabbit complement (Sera-Lab, Crawley, UK) was
reconstituted by dissolving one bottle in 2mls of distilled water. This was then added
to 20mls of CFD on ice. 50/xl of test serum was then added to 50/xl red blood cells and
50/xl rabbit complement and there after serial dilutions of serum from 1/5-1/1280
added to the reagents. The specimens were then incubated at 37°C for one hour, spun
at 1800rpm for 10 minutes and the supernatant absorbance read at 420nm in a
Multiscan Plate Reader (ICN, Costa Mesa, USA). The mean absorbance was
calculated for each sample and expressed as the area under curve (AUC) when
compared with a standard fixed human control with an AUC equivalent to lOOO.80
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Method for the measurement of anti-galactose a 1-3 galactose IgG and
IgM antibodies
Preparation of affinity purified anti-galactose a 1-3 galactose IgG and
IgM from pooled human serum
Quantification of anti-a gal antibody (AAG) levels in primate sera by microtitre plate
methods demands a standard preparation of purified AAG of known concentration and
representative binding characteristics. The antibody was prepared by fractionating
human serum on a column (7x0.5cm) of bovine thyroglobulin-sepharose-4B
(Pharmacia, St. Albans, UK) enriched for a- content by IB4 lectin affinity
chromatography. Separation on the thyroglobulin-sepharose column was performed in
the cold (4°C) at a flow rate of 1ml/minute. After applying the serum (approximately
900ml) the column was washed and specifically bound protein was batch-eluted with
two consecutive high temperature incubations (in 50mM Tris-HCL, 0.15M NaCl,
0.02% NaN3, 2x5 minutes at 57°C). The eluted material was further fractionated into
IgG and IgM fractions by gel filtration (using a Waters 300SW column controlled by a
Waters 650E chromatography work-station, as detailed below). The IgG and IgM was
then concentrated using ultra-filtration membranes (10 kDa exclusion) from Amicon.
Separation of IgG and IgM classes in serum by Gel-filtration
chromatography
Serum was spun at 10 000 rpm on a bench top centrifuge to eliminate insoluble
material. 50/xl was then fractionated by gel-filtration using a Waters 650 protein
purification system linked to a Waters 717plus autosampler (fitted with a cooler unit,
set at 4°C) and employing a Waters 300SW (300mm x 17mm) column.
Chromatography was performed at ambient temperature in 0.1M K2HPO4, 0.02%
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NaN3 at a flow rate of lml/minute. The A280 is monitored with a Waters model 481
UV spectrophotometer and the information fed to a BBC SE 120 chart recorder.
ELISA for quantification of anti-galactose a 1-3 galactose
immunoglobulin levels
Flexible 96-well microtitre plates were coated with 50/xl (5/ng/ml) of
neoglycoconjugate galactose a 1-3 galactose}) l-4GlcNAcetyl-human serum albumin
({gal a 1-3 gal(3l-4GlcNAc-HSA} Dextra Laboratories Ltd., Reading, UK) in coating
buffer (0.1 M sodium carbonate, pH 9.6) and left to absorb overnight at 4°C. The
plates were then thoroughly washed with phosphate buffered saline/azide (PBS tablets
from Sigma {Poole, Dorset, UK}- l/100ml) and supplemented with 0.02% sodium
azide) containing 0.1% globulin-free bovine serum albumin (BSA{Sigma, Poole,
Dorset, UK}). They were then blocked with 3% globulin-free BSA in PBS/azide (2
hours at room temperature).
IgM and IgG pools were taken to 1% BSA and applied in triplicate (50/d per well) to
the coated plate and the blocked control plate. Serial dilutions of affinity purified
human anti-a-gal IgG or IgM were then applied to the same plate (2-fold from 5/rg/ml
in 1% BSA in PBS). Coated and control plates were left to adsorb antibody for 2
hours at room temperature. After this period the plates were thoroughly washed with
0.1% BSA in PBS and overlaid with 50/tl horseradish peroxidase-conjugated anti-
human IgG or anti-human IgM (Sigma, Poole, Dorset, UK), and incubated for one
hour at room temperature. For development of colour, the wells were thoroughly
washed with PBS and incubated with 100/d of the substrate o-Phenylenediamine
(OPD {Sigma, Poole, Dorset, UK}) solution. When a strong yellow colour had
formed, the plate was quenched with 50/d 1M H2SO4 and the absorbance of the wells
read at 492nm with a Titertek Multiscan Plus plate reader. The mean absorbance of
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each serum sample was converted to /rg/ml antibody in the serum using a standard
curve constructed from the absorbances of the affinity-purified antibody preparations.
Diagnosis of xenograft rejection
Xenograft rejection was diagnosed as the cessation of cardiac xenograft pulsation
determined by abdominal palpation. This diagnosis was then confirmed histologically.
Histology
Donor
Ear clippings from each donor were stained with the mouse anti-human monoclonal
antibody BRIC 216 (IBGRL Research Products, Elstree, UK) to measure tissue
hDAF expression (see earlier).
Recipient
At the time of explant, the transplanted grafts were stained with haematoxylin and
eosin and examined histologically for each of the following:
The vascular endothelium was examined for cell retraction, white blood cell adherence,
endothelial permeability and rupture.
The vascular walls were examined for inflammation and vascular lumina for
congestion, thrombosis, fibrin and inflammatory cells.
Infiltration was recorded as either focal, diffuse or perivascular and the abundance of
neutrophils recorded as a measure of the infiltrate aggression.
The myocardium was examined for myocyte damage, myocytolysis and focal or
diffuse necrosis. Endocardial white blood cell adherence, permeability and disruption
were noted as was interstitial haemorrhage and oedema.
All histological parameters were graded semi-quantitatively on a scale of 0-4, where
0 = none, 1 = equivocal, 2 = mild, 3 = moderate and 4 = severe.
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Immunohistology
Cardiac tissue was snap-frozen in liquid nitrogen and stained for each of the following
immunohistological parameters using mouse anti-human C3, C4, C9 and IgG
monoclonal antibodies (mAbs)(Dako Ltd, High Wycombe, UK). Explanted grafts
were examined for galactose a 1-3 galactose expression. This was determined by
measuring the intensity of staining of biotinylated Griffoma (bandeirae) Simplicifolia
Lectin 1 (GSL: Vector, California, USA) which binds specifically to galactose a 1-3
galactose epitopes. Explanted grafts were also stained for the adhesion molecule P
selectin using a mouse anti-human mAb against P selectin (Immunotech, Hamburg,
Germany), Von Willebrand's Factor (VWF) using mouse anti-human mAb against
VWF (DAKO Ltd, High Wycombe, UK) and fibrin using mouse anti-human fibrin
mAb (DAKO Ltd, High Wycombe, UK). These parameters were measured semi-
quantitatively on a scale of 0-4 where 0 = no staining, 1 = equivocal staining, 2 =
mild staining, 3 = moderate staining and 4 = heavy staining.
The cellular infiltrate was evaluated in each graft by counting the number of cells per
five high power fields and representing this as the mean number of cells per high
power field (HPF). Tissue platelets were identified using mouse anti-human mAb
against P selectin (Immunotech, Hamburg, Germany). Neutrophils were identified
using mouse anti-human neutrophil mAb (DAKO Ltd, High Wycombe, UK), CD-4 T
helper cells using mouse anti-human CD-4 mAb (DAKO Ltd, High Wycombe, UK),
CD-8 T cytotoxic cells using mouse anti-human CD-8 mAb (DAKO Ltd, High
Wycombe, UK), CD-19 Bcells using mouse anti-human CD-19 mAb (DAKO Ltd,
High Wycombe, UK) and CD-68 macrophages using mouse anti-human CD-68 mAb
(DAKO Ltd, High Wycombe, UK).
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Statistical analysis
Analysis of survival data was performed using permutation tests on the ranked data
(Huntingdon Life Sciences Ltd, Huntingdon). Parametric data was analysed using the
two-tailed t test assuming unequal variances (Excel version 4.0). Non-parametric data
was analysed using the Mann-Whitney test (SPSS 7.5 for windows).
Results
13 control hearts, 11 heterozygous hDAF transgenic hearts and 1 homozygous hDAF
transgenic heart was transplanted heterotopically into the abdomen of non-
immunosuppressed cynomolgus monkeys.
The donor and recipient parameters can be seen in table 2.1. Note that there was no
significant difference in the control and transgenic groups in donor organ weight,
donor weight and age and recipient weight. The mean ischaemic time was similar in
both groups as was the country of origin of the primates; the large majority being from
the Philippines.
Parameter Transgenics Controls
Donor Weight (mean±SD) 2.5±0.6 kg 3.0±0.7 kg
Recipient Weight (mean ±SD) 2.6±0.7 kg 3.9±1.2 kg
Donor Age (mean±SD) 8.7±3.8 days 8.7±3.6 days
Ischaemic Time (mean±SD) 1.34±0.22 hours 1.6±0.5 hours
Recipient Country of Origin All Phillipino Phillipino (8), Mauritian (2)
Table 2.1. Non-immunosuppressed donor/recipient parameters.
Of the "technically successful" xenografts the heterozygous hDAF transgenic pig
hearts had a median beating time of 123 hours (range 97-126 hours) and the control
pigs hearts had a median beating time of 39 hours (range 0.4-104 hours {p<0.0001}).
The only homozygous hDAF transgenic pig heart transplanted had a beating time of
132 hours (figure 2.1), that is, greater than the best heterozygous heart. The control
49
group demonstrated a bimodal distribution of survival with five out of ten hearts
having a median beating time of 0.96 hours (range 0.4-8 hours) and five out of ten
hearts having a median beating time of 78 hours (range 69-104 hours).
The outcome can be seen in table 2.2.
Technical Outcome Recipient Genetics Beating Time (hours) Histology Other Cause of Failure
Success
W57 T 126 AVR
V428 T 106 AVR
W67 T 123 AVR
W58 T 122 AVR
W65 T 125 AVR
W62 T 97 AVR
W64 T 107 AVR
V517 T 123 AVR
W567 TT 132 AVR
T217 C 2.18 HAR
T365 C 1.18 HAR
V427 c 76 AVR
V519 c 80 AVR
V520 c 8 HAR
R701 c 0.73 HAR
T69 c 0.4 HAR
R690 c 69 AVR
W60 c 104 AVR
W69 c 101 AVR
Failure
R296 T 2 NER Sacrificed
V518 T 7 NER Sacrificed
V570 T 3 NER Sacrificed
V573 C 6.67 HAR Sacrificed
T405 C 4.5 HAR Sacrificed
V532 C 5.5 HAR Sacrificed
Table 2.2. Outcome of non-immunosuppressed pig-to-cynomolgus monkey cardiac
xenotransplantation.
T=heterozygous hDAF transgenic, TT=homozygous hDAF transgenic, C=control
(non-transgenic), AVR=acute vascular rejection, HAR=hyperacute rejection,

















Figure 2.1. Survival of control and transgenic pig hearts transplanted heterotopically
into non-immunosuppressed cynomolgus monkeys.
Total anti-pig antibody levels
We can see in figure 2.2 that there was a similar pattern in both the transgenics and the
long-surviving controls for both the preformed and elicited total anti-pig red blood cell
haemolytic antibody (APAb) levels. In general there was a high preformed natural
APAb level prior to transplantation, which fell immediately postoperatively almost to
zero (presumably due to immunoabsorption onto the graft). The elicited total APAb
level remained low until about the third postoperative day when it started to rise rapidly
resulting in graft loss in all cases by the fifth postoperative day. We can, however, see
that the control animals were less well able to tolerate high levels of elicited total APAb
and indeed the mean elicited total APAb levels in the control animals at the time of
sacrifice was 3260±1836 (range 1788-5936) compared with a mean elicited total
APAb levels in the recipients of transgenic hearts of 5629±1242 (range 3957-7055).
This difference did not however quite reach statistical significance. The elicited total




















Figure 2.2. Total anti-pig red blood cell haemolytic antibody levels in non-
immunosuppressed pig-to-cynomolgus monkey heterotopic cardiac transplantation.
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The preformed natural APAb levels also varied in each group. In the five recipients of
control hearts which stopped beating after only a few hours the mean level was 2149
(range 980-4247) compared with a mean level of 1376 (range 614-2051) for the long-
surviving controls. This difference was not, however, statistically significant. The
mean level for the recipients of heterozygous transgenic hearts was 518 (range 48-
1508) but this data did not follow a normal distribution and therefore any statistical
comparison must be made with caution. The mean preformed natural antibody level for
the single recipient of a homozygous transgenic heart was 1363. Although there was a
difference in the level of preformed natural total APAb for the heterozygote transgenics
compared with either group of controls the difference did not reach statistical
significance and there was no correlation between the preformed natural total APAb
and the graft survival time for any of the groups.
Anti galactose a 1-3 galactose IgG antibody levels
We can see from figure 2.3 that the serum anti-galactose a 1-3 galactose IgG antibody
levels in the cynomolgus recipients of heterotopic pig hearts remained fairly steady
both before and after transplantation and the pattern was similar for both the
transgenics and the long-surviving controls. All recipients tended to have levels both
before and after transplantation of less than 5ug/ml. There was, however, one
exception to this trend, namely recipient W62 who started with a pretransplant level of
20.4ug/ml which remained unchanged on the first post operative day, fell to a level of
13.8ug/ml by the second postoperative day and then remained steady. This suggests
that we were detecting levels of preformed AAG IgG and little in the way of an elicited
AAG IgG response as we might expect. There was also no significant difference in the
pretransplant AAG IgG levels in those controls which underwent HAR compared with

















Figure 2.3. Anti-galactose a 1-3 galactose IgG levels in non-immunosuppressed pig-
to-cynomolgus monkey heterotopic cardiac transplantation.
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Anti-galactose a 1-3 galactose IgM antibody levels
We can see from figure 2.4 that the serum AAG IgM antibody levels in the
cynomolgus recipients of heterotopic pig hearts followed a similar pattern in both the
transgenics and the long-surviving controls. The mean pretransplant level of
preformed AAG IgM in the transgenics was 11.0±4.lug/ml (range 4-17) and
24.7±14.5ug/ml (range 8-34) in the long-surviving controls. This difference was not,
however, statistically significant. There was also no significant difference in the
pretransplant AAG IgM levels in those controls which underwent HAR compared with
those controls which underwent AVR.
In both groups the post-transplant levels initially fell and then began to rise on the third
postoperative day. In the long-surviving controls the mean AAG IgM level at the time
of sacrifice was 28.7±4.2ug/ml (range 24-32) and in the transgenic was
88.5±40.4ug/ml (range 40-148) (p<0.01).
It would appear from these results that the rise in total APAb level seen prior to
rejection of the grafts was at least in part due to a rise in AAG IgM and suggests that
the expression of the transgene conferred some resistance to antibody mediated acute
vascular rejection.
Histology
All transgenic donor hearts scored 4 (scale of 0-4) for hDAF expression.
Histology showed florid HAR in 50% and AVR81 in 50% of the control hearts. There
was no evidence of HAR in the transgenic pig hearts, all being lost due to AVR (figure
2.6).
The results of the grading for the histological parameters, immunohistological
parameters and cell counts for non-immunosuppressed cynomolgus monkeys can be













Figure 2.4. Anti-galactose a 1-3 galactose IgM levels in non-immunosuppressed pig-
to-cynomolgus monkey heterotopic cardiac transplantation.
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Histology of transgenic grafts compared with hyperacute rejecting
control grafts
The median score for transgenic and hyperacute rejecting control grafts for endothelial
white blood cell adherence, endothelial permeability, vasculitis, congestion,
thrombosis, platelet thrombi, fibrin deposition, inflammatory cells, aggressive
infiltrate, diffuse haemorrhage, oedema and endocardial white cell adherence was from
3-4, there being no significant difference for each of these parameters.
The cellular infiltrate was aggressive in all grafts, there being no perivascular, focal, or
mild diffuse infiltrate observed. Haemorrhage was diffuse in all grafts, there being no
evidence of focal haemorrhage. The median score for endocardial permeability was 2
in the transgenic group and 3 in the hyperacute rejecting control group but this
difference was not statistically significant. The median score for endocardial disruption
was 2 in the transgenic group and 0 in the hyperacute rejecting controls, but again this
difference was not significant. Diffuse necrosis was present in all grafts, the median
score for the transgenic group being 4 and that for the hyperacute rejecting control
group being 2. This difference was not statistically significant. The median score for
endothelial rupture was 2 in the transgenic group and 3 in the hyperacutely rejecting
control group. The median score for myocytolysis was 0 in the transgenic group and 2
in the hyperacute rejecting control group. These differences did not reach statistical
significance.
The only non-immunohistological parameter for which there was a statistically
significant difference was myocyte damage, the median score being 0 in the transgenic
group and 3 in the hyperacute rejecting control group (p<0.05).
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Immunohistology of transgenic grafts compared with hyperacute
rejecting control grafts
All grafts had a score of 4 for endothelial C4 deposition. The median score for C3
endothelial deposition was 3 in the transgenic group and 4 in the hyperacute rejecting
control group. This difference was statistically significant (p <0.05). The median score
for C9 endothelial deposition was 3 for the transgenic group and 4 for the hyperacute
rejecting control group. This difference was statistically highly significant (p <0.005).
Fibrin deposition as detected immunohistologically had a median score of 4 in both
groups. There was no statistical difference between the two groups for IgG
deposition, staining for P selectin, deposition of VWF or GSL. 1 staining.
There was no statistically significant difference in the two groups for the number of
tissue platelets or tissue neutrophils expressed as the mean number/high power field.
When analyzing these results it must be remembered that we are comparing
histological changes in controls which had a median beating time of 0.96 hours with
transgenics which had a median beating time of 5.1 days.
Histology of transgenic and control technical failures
There were six technical failures in the non-immunosuppressed recipients: three were
transgenic and three were controls. The median beating time for the transgenics was 3
hours (range 2-7 hours) and for the controls it was 5.5 hours (range 4.5-6.7 hours).
This allowed us to analyse the effect of the transgene on the histological changes in
control and transgenic grafts at similar time points.
All three control hearts showed clear evidence of hyperacute rejection although the
actual cause of graft loss was due to technical reasons. For every histological
parameter the median score was higher in the controls than the transgenics, with the
exception of focal and perivascular infiltrate which was more frequently encountered in
the transgenic group as an aggressive infiltrate was more frequently seen in the control
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group. There was a statistically significant difference at the level of p<0.05 for each of
the following parameters- retracted endothelial cells, white blood cell adherence,
endothelial permeability, congestion, graft thrombosis, platelet thrombi, fibrin
deposition, presence of inflammatory cells, aggressive infiltrate, diffuse haemorrhage
and endocardial permeability.
Immunohistology of transgenic and control technical failures
In both the transgenic group and the control group the median score for C4 deposition
(figure 2.7) was 4. The median score for C3 deposition (figure 2.8) was 1 in the
transgenic group and 3 in the control group. This difference was statistically
significant (p<0.05). The median score for C9 deposition (figure 2.9) was 0 in the
transgenic group and 3 in the control group. This difference was statistically
significant (p<0.05). The median score for P selectin expression (figure 2.10) was 0
in the transgenic group and 2 in the control group. This difference was statistically
significant (p<0.05). The median score for fibrin deposition (figure 2.11) was 1 in the
transgenic group and 4 in the control group. This difference was statistically
significant (p<0.05). There was no difference in the amount of IgG deposition (figure
2.12) or GSL.l expression and although there was slightly more VWF expression in
the controls than the transgenics (4 vs 3), this difference did not reach statistical
significance.
Histology of transgenic grafts compared with long-surviving control
grafts
All grafts in these groups were lost due to AVR. Despite these control animals
surviving for an unexpectedly long time, the grafts were substantially damaged at the
time of rejection, but for most parameters there was no statistically significant
difference between the transgenic group and the long-surviving controls. Both groups
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had a median score of 4 for each of the following parameters- retracted endothelial
cells, endothelial white blood cell adherence, vascular congestion, intravascular
thrombosis, fibrin deposition, inflammatory cells, diffuse necrosis, aggressive
infiltrate and oedema. The median scores for endothelial rupture were 2 for the
transgenic and 4 for the control group. The median scores for endothelial permeability
were 3 for the transgenic and 4 for the control group. The median score for
endocardial white blood cell adherence was 3.5 for the transgenic group and 4 for the
control group and for endocardial disruption was 2 for the transgenic group and 3 for
the control group. None of these differences were statistically significant. There was
no myocyte damage and no myocytolysis in either group.
There was a statistically significant difference in the amount of diffuse haemorrhage (p
<0.05) and vasculitis (p<0.05) - the scores being 3 in the transgenics and 4 in the
control group. There was also a significant difference in the amount of endocardial
permeability (p <0.05) - the median score being 2 in the transgenic group and 4 in the
control group.
There was a significant difference in the amount of platelet thrombi (p <0.01) - the
median score being 3 in the transgenic group and 4 in the control group.
Immunohistology of transgenic grafts compared with long-surviving
control grafts
The median score for both the transgenic group and the control group was 4 for C4
deposition. The median score for the transgenic group for C3 deposition was 3
compared with a score of 4 for the control group. This difference was statistically
significant (p <0.05). The median score for C9 was 3 for the transgenic group and 4
for the control group. This difference was highly statistically significant (p <0.005).
There was a highly significant difference in the median scores for P selectin expression
(p <0.005) - being 3 for the transgenic group and 4 for the control group. There was
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also a statistically significant difference in the amount of GSL.l (p <0.01) - the score
being 3.5 for the transgenic group and 2 for the long-surviving control group. There
was no difference in the median scores for fibrin and IgG deposition, that being 4 in
both groups for the former and 3 in both groups for the latter. The median score for
VWF deposition was 3 in the transgenic group and 4 in the control group. This
difference did not reach statistical significance.
There was no difference in the number of tissue platelets per high power field. All cell
counts are expressed as mean / HPF ± SD. There were significantly more CD-4
T cells 61±27 vs 17±6 (p <0.05), CD-8 T cells 135±51 vs 53±24 (p <0.05)(figure
2.13) and CD-19 B cells 28±12 vs 10±4 (p <0.05) in the long-surviving control grafts
than in the transgenic grafts. There were also significantly more tissue neutrophils
196±63 vs 52±17 (p <0.01) and CD-68 macrophages 112±30 vs 50±16 (p <0.01) in
the long-surviving control grafts than in the transgenic grafts.
Histology of hyperacute rejecting control grafts compared with
long-surviving control grafts undergoing acute vascular rejection
There was significantly more endothelial rupture (p <0.05) in the long-surviving
controls than in the hyperacute-rejecting controls (median scores 4 vs 3). There was
more myocyte damage (3 vs 0) and myocytolysis in the hyperacutely rejecting controls
than in the long-surviving controls (2 vs 0) but this difference was not statistically
significant. There was more endocardial disruption in the long-surviving controls than
in the hyperacute rejecting controls (3 vs 0) but this difference was not statistically
significant. For all other histological parameters the median scores for both groups
were 3 or 4, there being no statistically significant difference between the two groups.
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Immunohistology of hyperacute rejecting control grafts compared with
long-surviving control grafts undergoing acute vascular rejection
The median score for GSL.l (figure 2.14) was 3 in the hyperacutely rejecting controls
and 2 in the long-surviving controls. This difference was statistically significant (p
<0.05). The median score for P selectin expression was 2 in the hyperacutely-rejecting
controls and 4 in the long-surviving controls. This difference was not statistically
significant. There was no statistically significant difference in the median scores for
C3, C4, C9, IgG, VWF or fibrin deposition, the score being 3 or 4 in all cases.
The mean number of tissue neutrophils per HPF was greater in the long-surviving
controls than in the hyperacutely-rejecting controls 196±63 vs 88±69(p<0.05). There
was no significant difference in the number of tissue platelets.
Histology and Immunohistology of the homozygous hDAF transgenic
pig heart compared with the heterozygous hDAF transgenic pig hearts
There was more myocyte damage (median score 4 vs 0), more myocytolysis (4 vs 0)
and more diffuse haemorrhage (4 vs 3) in the homozygous heart compared with the
heterozygous hearts. On the other hand, there was less endocardial adherence (2 vs
3.5), less endocardial disruption (0 vs 2) and less oedema (2 vs 4) in the homozygous
heart compared with the heterozygous hearts. Finally, there was no difference in any
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Histological Parameter
Median Score Statistical Significance
Transgenics Controls Transgenics vs. Controls
Retracted Endothelial Cells 1 4 D <0.05
White Blood Cell Adherence 1 4 D <0.05
Endothelial Permeability 0 4 D <0.05
Endothelial Rupture 0 3 NS
Vasculitis 0 3 NS
Congestion 2 3 p<0.05
Thrombosis 0 3 p <0.05
Platelet Thrombi 0 3 p <0.05
Fibrin 0 3 p <0.05
Inflammatory Cells 1 4 p <0.05
Myocyte Damage 0 0 NS
Myocytolysis 0 0 NS
Focal Necrosis 0 0 NS
Diffuse Necrosis 0 3 NS
Perivascular Infiltrate 1 0 NS
Focal Infiltrate 1 0 NS
Diffuse Infiltrate 0 0 NS
Aggressive Infiltrate 0 3 p <0.05
Focal Haemoirhage 0 0 NS
Diffuse Haemorrhage 0 3 p <0.05
Oedema 0 4 p<0 .05
Endocardial Adherence 0 3 p<0 .05
Endocardial Permeability 0 2 p <0.05
Endocardial Disruption 0 2 NS
Table 2.5. Grading and statistical significance of histological parameters for non-
immunosuppressed cynomolgus monkey technical failures. NS = not significant.
Immunohistological
Parameter
Median Score Statistical Significance
Transgenics Controls Transgenics vs. Controls
C3 1 3 p <0.05
C4 4 4 NS
C9 0 3 ©oV0
IgG 3 3 NS
P. selectin 0 2 p<0 .05
VonWillebrand's Factor 3 4 NS
Fibrin 1 4 p<0.05
GSL.l 3 3 NS
Table 2.6. Grading and statistical significance of immunohistological parameters







Moderate hDAF expression in
transgenic pig heart (xlO).
Strong hDAF expression in Positive control showing strong
transgenic pig heart (xlO). hDAF expression in human skin
(xlO).
Figure 2.5. Histology photographs demonstrating grading of human DAF
expression in tissues stained with BRIC 216.
Mild hDAF expression in
transgenic pig heart (xlO).
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Control heart (8 hours) undergoing hyperacute rejection with typical features
of thrombosis, haemorrhage, oedema, muscle damage and neutrophil
infiltration (xlO).
Control heart (76 hours) undergoing acute vascular rejection with typical
features of thrombosis, haemorrhage, severe muscle damage, neutrophil and
monocyte infiltration (xlO).
hDAF transgenic heart (123 hours) undergoing acute vascular rejection
with features of thrombosis, oedema, some muscle damage, neutrophil
and monocyte infiltration (xlO).
Figure 2.6. Sectioas of cardiac tissue stained with haematoxylin and eosin from
pig hearts transplanted heterotopically into non-immunosuppressed cynomolgus
monkeys.
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Control technical failure (6 hours) demonstrating heavy C4
deposition on the endothelium (xlO).
hDAF traasgenic technical failure (7 hours) demonstrating
heavy C4 deposition on the endothelium (xlO).
Figure 2.7. Sectioas of cardiac tissue stained for complement component C4
from pig hearts transplanted heterotopically into non-immunosuppnessed
cynomolgus monkeys.
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Control technical failure (6 hours) demonstrating clear C3
deposition on vascular endothelium (x20).
hDAF transgenic technical failure (7 hours) demonstrating
mild C3 deposition on vascular endothelium (xlO).
Figure 2.8. Sections of cardiac tissue stained for complement component C3















v, *■?. - Wnk
Control technical failure (6 hours) demonstrating heavy
C9 deposition within vessels and necrotic tissue (xlO).
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hDAF transgenic technical failure (7 hours) demonstrating
no C9 deposition (xlO).
Figure 2.9. Sectioas of cardiac tissue stained for complement component C9
from pig hearts transplanted heterotopically into non-immunosuppressed
cynomolgus monkeys.
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Control technical failure (6 hours) demonstrating heavy
P selectin deposition within the vessel (x20).
hDAF traasgenic technical failure (7 hours) demonstrating no
P selectin deposition (x20).
Figure 2.10. Sections of cardiac tissue stained for P selectin from pig hearts
transplanted heterotopically into non-immunosuppressed cynomolgus
monkeys.
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Control technical failure (6 hours) demonstrating heavy
fibrin deposition (xlO).
hDAF transgenic technical failure (7 hours) demonstrating
slight fibrin deposition (xlO).
Figure 2.11. Sections of cardiac tissue stained for fibrin deposition from pig
hearts transplanted heterotopically into non-immunosuppressed cynomolgus
monkeys.
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Control technical failure (6 hours) demonstrating heavy
IgG binding to endothelial cells (x20).
hDAF transgenic technical failure (7 hours) demonstrating
moderate IgG binding to endothelial cells (x20).
Figure 2.12. Sections of cardiac tissue stained for IgG from pig hearts
transplanted heterotopically into non-immunosuppressed cynomolgus
monkeys.
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Long-surviving control heart (101 hours) demonstrating
200 CD8 T cells per high power field (x20).
hDAF traasgenic heart (97 hours) demoastrating 17 CD8
T cells per high power field (xlO).
Figure 2.13. Sections of cardiac tissue stained for CD8 T cells from pig hearts
transplanted heterotopically into non-immunosuppressed cynomolgus monkeys.
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Hyperacute rejecting control heart (6 hours) demonstrating
heavy (4+) gal a gal staining(xlO).
Long-surviving control heart (82 hours) demonstrating moderate
(2+) gal a gal staining(xlO).
Figure 2.14. Sections of cardiac tissue stained for galactose a 1-3 galactose




Heterotopic abdominal heart transplantation from neonatal pig to cynomolgus monkey
is an exacting surgical technique and in this non-immunosuppressed model there were
six grafts which failed for technical reasons. However, this allowed us to collect and
analyse data on control and transgenic organs failing at similar time points and so
allowed us to make some important observations (see later). Of the remaining 19
technically successful operations carried out ten were performed using control
(normal) pigs, eight using pigs heterozygous for the hDAF transgene and one
homozygous for the hDAF transgene.
None of the transgenic grafts were hyperacutely rejected and the heterozygous
transgenics had a median beating time of 5.1 days. The single homozygous transgenic
had a beating time of 5.5 days. All transgenic grafts failed due to AVR.81 To our
surprise, half of the control grafts were hyperacutely rejected, with a median beating
time of 58 minutes and half failed due to AVR with a median beating time of 3.25
days. So it would appear that the hDAF transgene protects the xenograft against HAR
and indeed that homozygosity for the hDAF transgene may confer additional protection
over heterozygosity.
But, why should some normal pig hearts not undergo HAR when transplanted into the
cynomolgus monkey? Analysis of the total APAb levels, anti-agal IgG and IgM
levels and histology results may help to explain this unexpected observation (see
below). Does the level of preformed natural total APAb influence the outcome and
what influence does the elicited total anti-pig antibody level have on graft function?
In most recipients there was a high preformed natural antibody level prior to
transplantation which fell immediately following transplantation and this was
presumably due to immunoabsorption onto the graft. It is reasonable to suppose that
such binding of antibody to antigen may, under normal circumstances trigger HAR by
the classical pathway of complement activation. Although there was no statistically
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significant difference in the levels of preformed total APAb level in any of the groups,
the mean level in the hyperacutely-rejecting controls was 2149 compared with a mean
level for the long-surviving controls of 1376 and a mean level of 518 for the
heterozygote transgenics. The preformed total APAb data for the transgenic group did
not follow a normal distribution whereas those for the controls did, and so a direct
statistical comparison cannot be made for this data set. There was however, no
correlation between the preformed natural total APAb level and the graft survival time.
In general, the elicited total APAb level remained low until about the third
postoperative day when it started to rise rapidly resulting in graft loss in all cases by
the fifth postoperative day. At the time of graft loss due to AVR the mean elicited total
APAb level was 3260±1836 in the control animals and 5629±1242 in the transgenics,
suggesting that the expression of hDAF confers on the graft some additional protection
against the APAb.
In both groups the pre and post-transplant AAG IgG levels remained fairly constant
suggesting that it was neither AAG IgG which was immunoabsorbed onto the graft nor
was the elicited total antibody response due to AAG IgG. In contrast, the AAG IgM
levels both pre and post-transplant did indeed mirror the total APAb levels suggesting
that it was at least in part AAG IgM which bound to the xenograft at the time of
transplantation and that it was AAG IgM which may be responsible for graft damage at
the time of transplantation or indeed the triggering of HAR. In those grafts which were
not hyperacutely rejected the elicited antibody response from day three post-transplant
onwards appeared in part to be due to AAG IgM. Again, as with the level of total
APAb pre transplant there was also a difference in the pre transplant level of AAG IgM
in the transgenics and the long-surviving controls. The mean pretransplant level of
preformed AAG IgM in the transgenics was lower at 11.0±4. lug/ml than for the long-
surviving controls at 24.7±14.5ug/ml. This difference was not however statistically
significant. Although these levels did not appear to affect initial graft function it raises
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the possibility of some initial damage affecting later graft outcome. In the long-
surviving controls the mean AAG IgM level at the time of sacrifice was 28.7±4.2ug/ml
and in the transgenic was 88.5±40.4ug/ml. This difference was statistically significant
at the level p<0.01.
It would appear from these results that the rise in total APAb level seen prior to
rejection of the grafts was at least in part due to a rise in AAG IgM and that the
expression of the transgene confers some resistance to antibody mediated AVR.
Histological analysis demonstrated the classical features of HAR in half of the control
grafts - widespread graft thrombosis, fibrin deposition, endothelial disruption, diffuse
haemorrhage, oedema and an aggressive inflammatory cell infiltrate. These features
were also seen in the transgenic grafts. The only non-immunohistological parameter
for which there was a statistically significant difference between these two groups was
myocyte damage, the median score being 0 in the heterozygous transgenic group and 3
in the hyperacute rejecting control group (p<0.05). However, when comparing these
histological parameters one must take into consideration that we were comparing
control hearts with a median beating time of 0.96 hours with transgenic grafts with a
median beating time of 5.1 days. To compare these histological parameters at similar
time points for the two groups we can turn to the six transplants which failed for
technical reasons. Of the six transplants three were controls with a median beating time
of 5.5 hours and three were transgenics with a median beating time of 3 hours. Every
histological parameter indicated significantly more graft damage in the control hearts.
Immunohistological analysis of technical failure control hearts compared with technical
failure transgenic hearts demonstrated no difference in the amount of endothelial C4
deposition but significantly more endothelial C3 and C9 deposition in the control
grafts. This pattern was exactly as would be predicted from the mode of action of
hDAF since this complement regulator acts at the point of formation of the C3
convertases C4b2a and C3bBb (See chapter 1).
78
There was also significantly more P selectin expression in the technical failure control
group suggesting endothelial cell activation even at this early stage, with a score of 2 in
the controls and 0 in the transgenics. There was also evidence of greater activation of
the coagulation cascade in the control group with significantly more fibrin deposition
in the control grafts and slightly more Von Willebrand's factor deposition in the
controls, although this difference was not statistically significant.
Of the technically successful control grafts 50% were not hyperacutely rejected and
underwent AVR after a surprisingly long period and although most histological
parameters at the time of rejection were similar in both the long-surviving controls and
the transgenic grafts there was significantly more vasculitis, platelet thrombi, diffuse
haemorrhage and endocardial permeability in the long-surviving control group. There
was also significantly more P selectin expression in the long-surviving controls and a
significantly greater cellular infiltrate of CD-4 T cells, CD-8 T cells, CD-19 B cells,
CD-68 macrophages and tissue neutrophils.
There was a significant difference in the amount of GSL. 1 binding on the endothelium
of the grafts, with a median score of 3.5 for the transgenic group and 2 for the long-
surviving control group. It is this latter finding which may help to explain why these
control animals survived far in excess of what was expected. The relative lack of
antigenicity in this group may be of great importance. Indeed when compared with
those control grafts which were hyperacutely rejected there was a statistically
significant difference in the amount of GSL 1. binding, the score being 3 for the
hyperacutely rejecting controls. GSL.l binds specifically to galactose a 1-3 galactose
on endothelium of tissues and it this sugar residue which is thought to represent the
major antigenic epitope in xenotransplantation.
Histological analysis of the single homozygous graft demonstrated that there was less
endocardial adherence, endocardial disruption and oedema in the homozygous heart,
compared with the heterozygous hearts, but surprisingly more myocyte damage,
79
myocytolysis and diffuse haemorrhage. There was no difference in any of the other
histological or immunohistological parameters.
Finally, these results of heterotopic transplantation of normal and hDAF transgenic pig
hearts into non-immunosuppressed cynomolgus monkeys suggest that hDAF does
indeed confer protection against HAR. However, other factors may also be playing a
part and the antigenicity of the graft as measured by GSL1 binding is probably
important. In addition, it would appear that the level of preformed antibodies present in
the recipient at the time of transplantation, in the form of total anti-pig antibodies and
AAG IgM antibodies, may also influence graft function and the presence of hDAF on
the graft confers some degree of protection against the elicited total APAb and the
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Introduction
We have demonstrated in chapter two that hDAF transgenic pig hearts are not
hyperacutely rejected when transplanted into the cynomolgus monkey but that such
grafts stimulate a strong anti-pig antibody response which results in graft loss due to
acute vascular rejection. It is the aim of the experiments in this chapter to demonstrate
how the anti-pig antibody (APAb) response can be modulated with
immunosuppressive agents and therefore prolong graft survival. In this study we have
chosen a simple and clinically applicable regimen consisting of cyclosporin A (CyA),
cyclophosphamide (CyP) and steroids.
During the last fifty years, many immunosuppressive agents and modalities have been
used in the field of transplantation. In the 1950s, total body irradiation was shown to
induce immunosuppression and prolong survival of renal transplants in dogs. It was
first used in a human renal transplant recipient in 1958, but proved to be too toxic for
routine immunosuppression.82 The development of immunosuppressive drugs in the
1950s provided some hope that reducing the risk of rejection might be possible
without causing the severe toxicity associated with irradiation. One of the first
immunosuppressive agents to be identified was 6-mercaptopurine.83 It was first given
to the recipient of a human renal transplant in 1959.82 Shortly following this
azathioprine was used in a patient in 1961.84
The other principal agent to emerge at this time was the corticosteroid, prednisolone,
which was shown in 1963 to improve kidney graft survival in dogs.85 It is now
known that corticosteroids interfere with T cell proliferation through there ability to
block activation of the interleukin-1 and interleukin-6 genes.86 As a result, azathioprine
and prednisolone became the standard immunosuppressive agents throughout the
1960s and 1970s.
Cyclophosphamide has also been used in clinical practise for its immunosuppressive
effect in both arthritis87 and organ transplantation.88
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CyP is an alkylating agent which acts by disrupting cell growth, mitotic activity and
differentiation by cross-linking DNA strands. It therefore interferes with the normal
cell division in all rapidly proliferating tissues. It is however, potentially toxic with a
wide range of side-effects in humans, the most serious being bone-marrow
suppression, haemorrhagic cystitis, pneumonitis, pulmonary fibrosis and
cardiotoxicity, the latter three effects being thankfully rare. Gastrointestinal upset
although usually less threatening is also common.89
There is some in vitro evidence to suggest that CyP, being a cell cycle-specific agent,
is both toxic for inter mitotic and replicating cells and that it should be most effective if
therapy coincides with the period of extensive lymphoproliferation i.e. commenced
shortly after the immunological stimulus.90
Various other methods have been investigated. X-ray therapy over the transplant itself
appeared to prolong survival, while splenectomy and thymectomy reduced the body
lymphocyte pool.91 Antilymphocyte globulin91 was also developed as was thoracic
duct drainage.92
However, it wasn't until 1973 that cyclosporin A was purified from the fungi
Cylindrocarpon lucidum and Tolypocladium inflatum and found to have a marked
effect on both humoral and cell-mediated immunity.93 Further experiments showed that
CyA was able to suppress the rejection of heart allografts in rats94 and renal allografts
in dogs.95
A number of subsequent studies have shown that the predominant action of CyA is on
helper T lymphocytes, suppressing the production of lymphokines, particularly
interleukin-2.96
FK50697 is a macrolactam isolated from Streptomyces tsukubaeneis which blocks
IL-2 gene transcription and therefore has a similar effect to CyA.
Although standard immunosuppressive agents have proven highly effective for
allotransplantation, they are relatively impotent, when used alone, in preventing
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xenograft rejection. Suppression of anti-species antibodies is the main aim of
immunosuppression.
In this study CyP was chosen as the anti-B cell agent as prolonged survival of
hamster-to-rat heart xenografts has been demonstrated when CyP was combined with
Cyclosporin A.98 Methotrexate has also been shown to be effective in this model.99
In concordant primate xenotransplantation models such as cynomolgus monkey-to-
baboon heterotopic heart transplantation the simple combination of CyA and
prednisolone has resulted in a mean graft survival of 77 days.100 Total lymphoid
irradiation in combination with CyA and prednisolone has resulted in survival of
cynomolgus monkey hearts transplanted heterotopically into baboons for greater than
480 days.101
The combination of CyA, prednisolone, FK506 and methotrexate has resulted in graft
survival in an orthotopic heart transplantation model from rhesus monkey to baboon of
up to 500 days.102
Predictably, however, discordant pig-to-primate xenotransplantation has been less
successful. Pig hearts transplanted heterotopically into Japanese monkeys,
immunosuppressed with FK506 and nafamstat mesilate (complement inhibitor), in
combination with splenectomy and double filtration plasmapheresis resulted in graft
survival of only 270 minutes.103
The combination of cobra venom factor, splenectomy, CyA, prednisolone, CyP and
methotrexate has resulted in pig-to-baboon heterotopic cardiac xenograft survival of 25
days.104
Continuous infusion of soluble complement receptor type 1 (sCRl) and
immunosuppression of cynomolgus monkeys with CyA, CyP and steroids resulted in
heterotopic pig cardiac xenograft survival for up to 32 days, the monkey being
sacrificed due to systemic infection.105
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Materials and Methods
Donor and recipient selection
The criteria used for donor and recipient selection and the code of practise followed are
described on pages 38-39.
In addition all monkeys selected as recipients were screened for total anti-pig red blood
cell haemolytic antibodies and only those with antibody levels greater than a pool of
human sera were used as recipients so that the transgene would be tested to a degree
which would attempt to reproduce the clinical pig-to-human situation.
Donor and recipient operations and postoperative management
A full description of the donor and recipient operations and the postoperative
management is described on pages 40-43.
Immunosuppression
All recipient cynomolgus monkeys were immunosuppressed with a combination of
CyA, steroids and CyP, the doses and schedule being summarised in table 3.1 and
described in greater detail below.
Cyclosporin A
All animals received CyA, commencing on the day prior to transplantation, to achieve
trough levels of 400 ng/ml. CyA was administered for the first 5 days intramuscularly
(Sandimmun) and thereafter orally (Neoral).
Steroids
Methyl prednisolone treatment was commenced at Img/kg/day reducing to
0.2mg/kg/day by day 18.
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Cyclophosphamide
Two CyP regimens were used:
Group 1 (n=10)- CyP was given on the preoperative day at 40mg/kg, operative day
at 20mg/kg and second postoperative day at 40mg/kg and alternate days thereafter,
tailored to the white cell count (wee) and the anti-pig antibody (APAb) levels.
Group 2 tn=5T no CyP until day two at 40mg/kg and day three at 20mg/kg and
thereafter only if indicated by a rising APAb level.
All control animals (n=5) were commenced on the group 1 CyP regimen.
CyP was temporarily discontinued if the total wee fell below 2xl06 cells /ml and was
usually increased if the APAb level started to climb.















0.2mg/kg by day 18
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Table 3.1. Immunosuppressive regimen. i.m.=intramuscular, i.v.=intravenous,
APAb=anti-pig haemolytic red blood cell antibodies, wcc=white cell count.
Blood sampling and monitoring
Blood was sampled regularly for total anti-pig haemolytic antibody (APAb) levels (as
described in chapter two), trough CyA levels (thin-layer chromatography, Papworth
Hospital), full blood count and differential wee (Bayer-Technicon haematology
analyser), electrolytes and creatinine (Hitachi 737 clinical chemistry analyser) and the
immunosuppression was tailored accordingly (table 3.1).
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Diagnosis of xenograft rejection




All donor ear clippings were scored for hDAF expression as described in chapter 2.
Recipient
All explanted hearts were examined histologically by staining with haematoxylin and
eosin (H+E) and immunochemistry for all parameters as described in chapter two.
Bone marrow
Bone marrow from selected recipients was stained with Giemsa and examined for the
presence of leukoerythroblastic precursors.
Bowel
Small and large bowel from those recipients developing diarrhoea was stained with
H+E and carefully examined to elucidate the aetiology for the diarrhoea.
Statistical analysis
Analysis of survival data was performed using permutation tests on the ranked data
(Huntingdon Life Sciences Ltd, Huntingdon). Parametric data was analysed using the
two-tailed t test assuming unequal variances (Excel version 4.0). Non-parametric data
was analysed using the Mann-Whitney test (SPSS 7.5 for windows).
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Results
Fifteen heterozygous transgenic and five control hearts were transplanted
heterotopically into the abdomen of immunosuppressed cynomolgus monkeys. Of the
transgenic hearts ten were immunosuppressed with the high CyP regimen (group 1)
and five were immunosuppressed with the low CyP regimen (group 2). All control
hearts were immunosuppressed with the high CyP regimen. The donor and recipient
parameters can be seen in table 3.2.
Parameter Group 1 Group 2 Controls
Donor Weight (mean±SD) 2.74±0.6 kg 3.34±0.88 kg 2.97±0.79 kg
Recipient Weight (mean±SD) 2.35±0.4 kg 3.06±0.26 kg 2.44+0.16 kg
Ischaemic Time (mean±SD) 1.31 ±0.26 hours 1.72±0.44 hours 1.63±0.18 hours
Recipient Country of Origin Mauritius Mauritius Mauritius
Table 3.2. Immunosuppressed donor /recipient parameters.
Note that there was no significant difference in the control, high CyP or low CyP
transgenic groups in the mean donor weight or recipient country of origin. However,
the group 2 (low CyP) recipients had a slightly greater recipient mean body weight
than either the group 1 (high CyP transgenic group) or the controls. This reached
statistical significance at p<0.01. The mean ischaemic time was also significantly
longer (p<0.05) for the control grafts when compared with group 1 grafts, but not
when compared with group 2 grafts. The outcome can be seen in table 3.3.
The hDAF transgenic hearts in the high CyP group had a median beating time of 40
days (range 6-62 days) compared with 9 days (range 8-34 days) for those in the low
CyP group (figure 3.1). This difference was statistically significant (p <0.05). The
control grafts had a median beating time of 55 minutes (range 2-180 minutes). The
difference between the control grafts and the high CyP transgenics was statistically
highly significant (p <0.001). The difference between the control grafts and the low
CyP transgenics was also statistically significant (p <0.05).
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Recipient Genetics Immunosppression Beating Time Histology Cause of Failure
W142 T High CyP 6 days AVR Rejection
W141 T High CyP 34 days NER (E) Diarrhoea
W140 T High CyP 35 days NER (E) Diarrhoea
W326 T High CyP 45 days NER (E) GI Bleed
W143 T High CyP 54 days NER Cardiomyopathy
W323 T High CyP 28 days NER (E) Diarrhoea
W374 T High CyP 8 days NER (E) Peritonitis
W328 T High CyP 57 days NER (E) Diarrhoea
W333 T High CyP 55 days NER Not identified
W341 T High CyP 61 days AVR Rejection
W544 T Low CyP 34 days AVR Rejection
W554 T Low CyP 10 days AVR Rejection
W112 T Low CyP 8 days AVR Rejection
W445 T Low CyP 9 days AVR Rejection
W459 T Low CyP 8 days AVR Rejection
W428 C High CyP 2 minutes HAR Rejection
W434 C High CyP 35 minutes HAR Rejection
W427 C High CyP 55 minutes HAR Rejection
W430 C High CyP 180 minutes HAR Rejection
W431 C High CyP 60 minutes HAR Rejection
Table 3.3. Outcome of immunosuppressed pig-to-cynomolgus monkey cardiac
xenografts. T=transgenic, C=control, CyP=cyclophosphamide, AVR=acute vascular
rejection, NER=no evidence of rejection, (E)=euthanased.
All control hearts were hyperacutely rejected. Only two hearts in the high CyP group
were rejected, on days 6 and 62: all other hearts showed no evidence of rejection. Both
rejected hearts demonstrated AVR histologically, but the heart which was rejected on
day six was shown histologically to express very little hDAF on it's endothelium. This
was also the first cynomolgus recipient to be immunosuppressed and it was clear that
cynomolgus monkeys do not absorb CyA and CyP with the same profile as humans.
As a result inadequate doses of drugs were administered to this recipient and the heart
was rejected on day six. Of the remaining eight animals in the high CyP group, one
heart failed due to a cardiomyopathy on day 54 and one heart stopped beating on day
55 but there was no evidence of rejection and no cause for it's failure identified. The
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Days Post Transplantation
Figure 3.1. Survival of control and transgenic pig hearts in immunosuppressed
cynomolgus monkeys.
other six animals were sacrificed with beating cardiac xenografts in compliance with
Home Office Animal Welfare guidelines as a result of gastrointestinal complications.
One recipient was sacrificed on day eight due to peritonitis secondary to an intra
abdominal abscess adjacent to the graft, one recipient was sacrificed following a
gastrointestinal bleed secondary to colonic polyps and the remaining four recipients
were sacrificed with intractable diarrhoea. No infective agent was identified by
repeated blood and stool culture. All hDAF transgenic hearts in the low CyP group
underwent AVR. The survival and outcome for the recipients of transgenic pig hearts
is summarised in table 3.3.
Immunosuppression
Cyclophosphamide dose
The mean CyP dose received by the recipients in group 1 perioperatively and during
the first nine days postoperatively was 17.9±3.6mg/kg/day compared with
10.3±1.9mg/kg/day in group 2 (p<0.001). This represented a 45% reduction in dose
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(figure 3.2). Beyond day nine little data exists for group 2. However, the mean dose
received by group 1 recipients from the ninth postoperative day onwards was
6.4±2.0mg/kg/day compared with 4.4mg/kg/day for W544, the only group 2 recipient
surviving beyond day nine. Hence, the two methods of CyP dosing resulted in a
significantly greater amount of CyP being administered perioperatively, and in the
early postoperative period, in group 1 but smaller and comparable doses being













Group 1 Group 2
Figure 3.2. Mean cyclophosphamide dose received by recipients during the first nine
days following transplantation.
Cyclosporin A dosing and levels
CyA was administered intramuscularly at a dose of 25mg/kg for the first five days in
both groups and thereafter orally in two divided doses with the aim of achieving
plasma CyA levels of 400ng/ml. In group 1 the mean plasma CyA level achieved was
554±70.7ng/ml with a mean total daily CyA dose required to achieve this level of
122±19.9mg/kg (range 40-350mg/kg).
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In group 2 the mean plasma CyA level achieved was 876±291ng/ml with a mean total
daily CyA dose required to achieve this level of 109±9.1mg/kg (range 60-155mg/kg).
There was no significant difference in the CyA dose administered in either group and
although the CyA level achieved in group 2 was greater this did not quite reach
statistical significance (p=0.07).
Creatinine levels
Plasma creatinine levels remained within normal limits (0.5-0.8mg/dl) for all recipient
cynomolgus monkeys receiving CyA in both groups.
Total white cell count
The mean total wcc fell to 2.1±0.83xl06/ml (normal range 6-17.1xl06/ml) by the
eighth postoperative day in group 1 but only fell to it's lowest point of
4.7±0.91xl06/ml on the seventh postoperative day in group 2 (figure 3.3). Note that
the mean total wcc was slightly higher in the group 2 recipients at the start of the
experiment. Despite this, the pattern of change in the mean total wcc was broadly
similar in both groups during the first 15 days.
The sharp fall in mean total wcc seen on day three in group 1 wasn't seen in group 2
until day four. In both groups the early reduction in CyP dose resulted in a slight
recovery of the wcc on days four and five in groups 1 and 2 respectively. This was
also associated with a concomitant rise in total APAb levels in both groups and
therefore additional doses of CyP (see figures 3.11 and 3.12) were administered with
a resultant further fall in mean total wcc. Beyond day ten the data for group 2 relates to
only one recipient, i.e.W544, compared with eight recipients for group 1, hence a
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Figure 3.3. Mean total white cell count in high and low cyclophosphamide groups
during the first 15 days following transplantation.
Figure 3.4. Mean total white cell count in high and low cyclophosphamide groups
following transplantation.
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However, we can see from figure 3.4 that the mean total wee for group 1 remained
consistently between 2 to4xl06 cells/ml, whereas the total wee for the single recipient
in group 2 varied widely from 3 to 12xl06 cells/ml.
Lymphocyte count
We can see from figure 3.5 that the mean lymphocyte count in group 1 fell from a
preoperative level of 7xl06/ml (normal range 3.5-12.5xl06/ml) to 2xl06/ml on the first
postoperative day. The mean lymphocyte count in group 2, however, started at a
preoperative level of 4.2x106/ml and remained about this level for the first few days
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Figure 3.5. Mean lymphocyte count in high and low cyclophosphamide groups.
In group 1 the mean lymphocyte count slowly fell from 2xl06/ml to lxl06/ml during
the first 20 postoperative days and then fluctuated between 0.5 to lxl06/ml thereafter.
In group 2 there was a greater fluctuation in the downward trend beyond the seventh
postoperative day between 1.0xl06/ml and 2.5xl06/ml. The level in group 2 remained
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higher than in group 1 for most of the time. Beyond day ten the data for group 2
relates to only one recipient, i.e.W544, compared with eight recipients for group 1,
hence a detailed comparison cannot be drawn during this period.
Neutrophil count
We can see from figure 3.6 that there was a marked rise in the mean neutrophil counts
in both groups immediately following transplantation (normal range 0.9-7.5xl06/ml).
This was followed in both groups by a sharp fall in the mean neutrophil count,
followed by a more gradual fall to the tenth postoperative day. Beyond day 10 the
mean neutrophil count was seen to vary from 0.5x106/ml to 3.0x106/ml in the group 1

















Figure 3.6. Mean neutrophil count in high and low cyclophosphamide groups.
Haemoglobin concentration
The postoperative haemoglobin (Hb) concentration (normal range 10.2-13.7g/dl) fell
by similar amounts in both groups (figure 3.7). There was an initial sharp fall noted by
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the first postoperative day followed by a steady decline in Hb concentration thereafter.
There was a mean fall of 4.25±1.5g/dl (26±11% of preoperative Hb) in group 1 and
3.5±1.9g/dl (27.4±14% of preoperative Hb) in group 2 by the ninth postoperative
day. This difference was not significant. The pattern of change in the mean Hb
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Figure 3.7. Mean haemoglobin concentration in high and low cyclophosphamide
groups.
tenth postoperative day represents a single recipient). The mean Hb concentration in
group 1 fell from its preoperative level of 12.9±0.7g/dl to 8.35±1.5g/dl by the sixth
postoperative day. The mean Hb concentration in group 2 fell from it's preoperative
level of 13.8±0.4g/dl to a low point of 9.3±1.2g/dl by the ninth postoperative day.
Thus although the fall in Hb concentration followed a similar pattern in both groups,
there was a lag in the fall in group 2 as might be expected from the dosing pattern of
CyP. Following this initial fall there was a partial recovery of the Hb concentration by
the 17th postoperative day to 10.8±1.2g/dl in group 1 and 10.7g/dl in group 2.
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Beyond this point there was a steady and continuous fall in the Hb concentration in
both groups (note group 2 is represented by W544 only) at a rate of 0.2g/dl/day.
Platelet count
We can see from figure 3.8 that in group 1 the mean platelet count fell (normal range
280-650x106/ml) from it's preoperative value of 341±29xl06/ml to 269±74xl06/ml on
the first postoperative day and that this was then followed by a reactive thrombocytosis
which reached a level of 429±124xl06/ml on the tenth postoperative day. Beyond the
tenth postoperative day the platelet count gradually fell until it reached a level of










10 20 30 40 50
Days Post Transplantation
Group 1 (High CyP)
O Group 2 ( Low CyP)
Figure 3.8. Mean platelet count in high and low cyclophosphamide groups.
In group 2 the mean platelet count fell from it's preoperative value of 305±46xl06/ml
to 168±59xl06/ml on the first postoperative day and was then followed by a reactive
thrombocytosis which reached a level of 286±112xl06/ml on the fifth postoperative
day.
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Unlike group 1, which had it's peak platelet count on day ten, the platelet count in
group 2 fell on day ten to 178±33xl06/ml (note that there is insufficient data in group 2
beyond day ten to draw a comparison).
Total anti-pig antibody levels
We can see in figure 3.9 that the preformed natural total APAb levels in group 1 prior
to transplantation were high and that these immediately fell almost to zero following
transplantation (presumably due to immunoabsorption onto the graft). Indeed the mean
preformed APAb level in group 1 was 1542±246. The elicited total APAb levels, in
general, remained low until about the third postoperative day, at which time they began
to rise and then tended to peak by the fifth postoperative day. Beyond the fifth
postoperative day there were a variable number of peaks and troughs of antibody
levels. The amplitude of these peaks also varied widely. Despite the many antibody
peaks, however, only two resulted in xenograft rejection i.e. that on day six which
resulted in graft rejection in recipient W142 and that on day 61 which resulted in graft
rejection in recipient W341.
The preformed natural total APAb levels in group 2 (figure 3.10) followed a similar
pattern to those in group 1, being high (mean 1700±276) and then falling almost to
zero immediately following transplantation. Indeed there was no statistical difference
in the levels of the pretransplant APAb levels.
In contrast, the pattern of elicited total APAb levels and their effect on graft viability in
group 2 was markedly different. The levels initially remained low until about the fifth
to eighth postoperative days, at which time there was again an increase in antibody
levels in four out of five recipients which resulted in every case in xenograft rejection.
The only recipient in group 2 in which there wasn't an antibody increase around this
time was W544. In W544 the elicited total APAb level remained low until the 24th
postoperative day at which time there was a small peak and a later increase in antibody
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level on the 33rd postoperative day resulted in xenograft rejection. We can see in
figure 3.11 that the pretransplant total APAb level in recipient W141 (group 1) fell to
almost zero following transplantation and that the total wcc initially rose. Despite the
pre and perioperative CyP doses, the elicited total APAb level started to rise until the
eighth postoperative day, at which time the total APAb level again fell and remained
suppressed until day 14. Note that in response to the rising APAb level the dose of
CyP was increased to 40mg/kg given for three consecutive doses at alternate day
intervals. This resulted in a falling total wcc, which by day ten was almost zero and so
no further CyP was given until 14, at which time the total wcc had started to recover.
CyP was then given in 20mg/kg doses on alternate days in an attempt to suppress both
the total wcc and the antibody level. Despite this maintenance dose of CyP the total
APAb level started to rise again on day 20 and reached a peak on day 24. In response
to the rising APAb level the CyP dose was further increased on day 21 which resulted
in a falling total wcc and a falling APAb level beyond day 24. The recipient was
sacrificed under Home Office guidelines with a beating cardiac xenograft due to
intractable diarrhoea and poor general condition.
We can see in figure 3.12 that the pretransplant total APAb level in recipient W554
(group 2) fell to almost zero following transplantation and that the total wcc initially
rose in exactly the same way as with W141. However, on this occasion no pre or
perioperative CyP was given, the first dose of CyP being 40mg/kg on the second
postoperative day. The elicited total APAb level remained low until a modest spike on
day nine resulted in xenograft rejection on day ten, despite additional CyP doses
between days eight and ten, even in the face of a low total wcc.
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Histology
All transgenic donor hearts scored 4 (scale of 0-4) for hDAF expression except that
heart which was transplanted into recipient W142. At the time of explant of this pig
heart it was found to express only 1+ of hDAF on it's endothelium.
Histological examination of postmortem cardiac xenografts demonstrated florid HAR
in all five control hearts (figure 3.13). There was no evidence ofHAR in any of the 15
transgenic hearts. Two of ten transgenic hearts in group 1 (high CyP) were lost due to
AVR: the remaining eight hearts in this group showed no evidence of rejection (figure
3.13). Of these eight hearts one failed due to a dilated cardiomyopathy and one heart
stopped beating on day 55, but there was no evidence of rejection and no cause for it's
failure identified. The other six animals were sacrificed with beating cardiac xenografts
in compliance with Home Office Animal Welfare guidelines as a result of
gastrointestinal complications. All hDAF transgenic hearts in group 2 (low CyP)
underwent AVR resulting in graft loss (figure 3.13).
The results of the grading for the histological parameters, immunohistological
parameters and cell counts for immunosuppressed cynomolgus monkeys can be seen
in tables 3.4. and 3.5.
Histology of group 1 hearts compared with controls
The median score for all histological parameters for group 1 xenografts was 0, there
being no evidence of inflammation, cell damage or infiltrate. This contrasted markedly
with the controls which had a median score of 4 for all but two histological parameters
i.e. diffuse necrosis for which the controls had a median score of 1 and oedema for
which the controls had a median score of 2.5. The only parameter for which this
difference did not reach statistical significance was diffuse necrosis. The difference for
congestion, focal necrosis, perivascular infiltrate, focal infiltrate, focal haemorrhage
and oedema was significant at the level p<0.05. The difference for white blood cell
104
adherence, platelet thrombi, diffuse infiltrate and aggressive infiltrate was significant at
the level p<0.01. The difference for retracted endothelial cells, endothelial
permeability, endothelial rupture, vasculitis, thrombosis, fibrin, inflammatory cells,
myocyte damage, myocytolysis, diffuse haemorrhage and endocardial white blood cell
adherence was significant at the level p<0.005. The difference for endocardial
permeability and endocardial disruption was significant at the level pcO.OOl.
Immunohistology of group 1 hearts compared with controls
The median score in the control xenografts was 4 compared with a median score of 2
or lower for each of the following parameters: C3 (figure 3.14), C9 (figure 3.15),
P selectin and Von Willebrand's Factor (VWF). This was statistically significant at the
level p <0.005.
The median score in both the controls and the group 1 xenografts was 3 for C4. The
median score for IgG deposition was 3 in group 1 and 4 in the controls, there being no
significant difference. The median score for biotinylated griffonia simplicifolia lectin 1
(GSL.l), staining for gal a gal residues, was 3 in group 1 and 2 in the control
xenografts, there being no significant difference.
There was no significant difference between the two groups for either the mean
number of tissue platelets or tissue neutrophils per high power field.
Histology of group 2 hearts compared with controls
The difference between group 2 and the control xenografts for each of the following
parameters was significant at the level p<0.05: retracted endothelial cells, white blood
cell adherence, endothelial permeability, thrombosis, platelet thrombi, fibrin,
inflammatory cells, myocytolysis and focal necrosis. The median score for each of
these parameters for group 2 xenografts was 2 to 2.5 compared with a median score
for control xenografts of 4.
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Again, there was a significant difference between group 2 and the control xenografts
for each of the following parameters at the level p<0.01: endothelial rupture, with
median scores of 1 vs 4, endocardial white cell adherence (2 vs 4), endocardial
permeability (2 vs 4) and endocardial disruption (0 vs 4).
Finally, there was no significant difference between the two groups (group 2
xenografts having a median score of 3 to 4 and control xenografts a median score of 4)
for each of the following histological parameters: congestion, myocyte damage,
perivascular infiltrate, focal infiltrate, diffuse infiltrate and aggressive infiltrate. There
was no significant difference between the two groups for oedema, the median score
being 3 for group 2 and 2.5 for control xenografts, or diffuse necrosis, the median
score being 1 for both group 2 and control animals.
Immunohistology of group 2 hearts compared with controls
For each of the following immunohistological parameters there was a significant
difference between group 2 and the control xenografts at the level p<0.05: C3 (figure
3.14), C9 (figure 3.15), VWF and GS1.1 The median score for each parameter was 3
in group 2 and 4 in the control group. There was significantly more GSL. 1 staining
(p<0.05) in group 2 than in the controls (3 vs 2). There was also a significant
difference between group 2 and the control xenografts at the level p<0.005 for P-
selectin only, the median score for group 2 being 1 and the control xenografts being 4.
There was no significant difference between the two groups for either C4, or IgG: the
median score being 3 or 4 in each and finally, there was no difference in the mean
number of tissue platelets or the mean number of tissue neutrophils per high power
field in the two groups.
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Histology of group 1 hearts compared with group 2 hearts
All histological parameters for group 1 transgenic xenografts had a median score of 0,
there being no evidence of inflammation, cell damage or infiltrate for eight of the ten
cardiac xenografts. The remaining two demonstrated evidence of AVR on days 6 and
62. Similarly, group 2 xenografts had median scores of 0 to 1 for diffuse necrosis,
endothelial rupture and endocardial disruption, there being no significant difference
between the two groups for these parameters. The median score in group 2 transgenic
xenografts was 2 to 2.5, but not statistically different compared with group 1
xenografts for each of the following parameters: retracted endothelial cells, white
blood cell adherence, endothelial permeability, vasculitis, myocytolysis and
endocardial adherence. In group 2 transgenic xenografts the median score was 3 to 4
and again this was not statistically different compared with group 1 xenografts for each
of the following parameters: platelet thrombi, myocyte damage, focal necrosis,
perivascular infiltrate and focal haemorrhage.
However, the median in group 2 transgenic xenografts was 2 to 2.5 and this difference
was statistically significant, compared with group 1 xenografts, at the level p<0.05 for
each of the following parameters: aggressive infiltrate, diffuse haemorrhage and
endocardial permeability. For each of the following parameters: congestion,
thrombosis, fibrin, inflammatory cells and focal infiltrate the median score in group 2
transgenic xenografts was 3 to 4 and was statistically different at the level p<0.05. The
median score in group 2 transgenic xenografts for oedema was 3 vs 0 for group 1
xenografts and this was also significant at the level p<0.05.
Finally, the median score in group 2 transgenic xenografts for diffuse infiltrate was 4
vs 0 for group 1 xenografts and this reached statistical significance at the level p<0.01.
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Immunohistology of group 1 hearts compared with group 2 hearts
There was a significant difference (p<0.05) between group 1 and group 2 xenografts
for VWF staining (2 vs 3) and a difference (p<0.01) for C3 (1 vs 3) and C9 deposition
(0.5 vs 3). There was no difference between the two groups for either C4, IgG, or
GSL.l staining, both groups having a median score of 3 for each parameter. Nor was
there a significant difference between the two groups for P selectin, the mean number
of tissue platelets or the mean number of tissue neutrophils. A significant difference
was found between group 1 and group 2 xenografts at the level p<0.05 for the mean
number of CD-4 T cells, being 1±2.4/HPF in group 1 and 7±3.6/HPF in group 2 and
the mean number of CD-8 T cells, being 8±8.9/HPF in group 1 and 23±10.8/HPF in
group 2. There was no significant difference in the number of CD-19 B cells in each
group.
It should be noted, however, that the sample numbers in these groups are small and
that the mean cell counts for group 1 have large standard deviations indicating a large
spread of results about the mean in a group which does not appear to contain
completely parametric data (in this group two grafts were rejected and eight were not).
Any conclusions about the mean cell counts in group 1 should therefore be treated with
caution.
Histology of bone marrow
Histological examination of bone marrow of recipients of xenografts in both groups
demonstrated no evidence of marrow suppression with a normal number of
leukoerythroblastic precursors (figure 3.16).
Histology of bowel
Histological examination of sections of small and large bowel from those animals in
group 1 which were sacrificed due to intractable diarrhoea demonstrated a non-specific




























































































































































































































































































Table3.5.Gradingandstatisticalsig ficanceofimmunohistologi alparametersf rimmunosuppressedcynomo gusm nk ys. NS=notsignificant,HPFhi hpowerfield. NotethdifferenceinC3,9Ps le tina dVonWillebra d'sF ctorthransg icgraftontrol .A tet significantlyincreasedTcellinf ltrateoup2(lowcyclophosphamide)x n graftscomp redwitgroup1(h cyclophosphamide)xenografts.
Control heart (35 mins) showing typical features of hyperacute rejection -
thrombosis, haemorrhage, myocyte damage and neutrophil infiltration (xlO).
Group 1 hDAF transgenic heart (45 days) showing no rejection, with preservation
of myocytes, no haemorrhage or thrombosis and clear blood vessels (xlO).
Group 2 hDAF transgenic heart (8 days) showing severe acute vascular
rejection, with gross disruption ofmyocardial architecture, severe
haemorrhage, and thrombosis with neutrophil infiltration (xlO).
Figure 3.13. Sections of cardiac tissue, stained with haematoxylin and eosin, from
heterotopically transplanted pig hearts, immunosuppressed with the group 1 (high
cyclophosphamide) or group 2 (low cyclophosphamide) regimen.
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Group 1 hDAF transgenic heart (45 days) showing moderate C3 deposition (xlO).
Group 2 hDAF traasgenic heart (8 days) showing heavy C3 deposition on
the endothelium of a large blood vessel (x20).
Figure 3.14. Sections of cardiac tissue, stained for complement component C3, from
heterotopically transplanted pig hearts, immunosuppressed with the group 1 (high
cyclophosphamide) or group 2 (low cyclophosphamide) regimen.
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Group 1 hDAF transgenic heart (45 days) showing moderate C9 deposition (x 10).
Group 2 hDAF transgenic heart (8 days) showing heavy C9 deposition (x20).
Figure 3.15. Sections of cardiac tissue, stained for complement component C9, from
heterotopically transplanted pig hearts, immunosuppressed with the group 1 (high
cyclophosphamide) or group 2 (low cyclophosphamide) regimen.
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Figure 3.16. Histology photograph showing bone marrow stained with
Giemsa from a group 1 (high cyclophosphamide) cynomolgus monkey.
Note the normal leukoerythroblastic precursors in this immunosuppressed
recipient (xlO).
Figure 3.17. Histology photograph showing a section of bowel stained
with haematoxylin and eosin from a group 1 (high cyclophosphamide)
cynomolgus monkey which was sacrificed because of the development of
intractable diarrhoea Note the inflammatory infiltration and disruption of
the epithelium consistent with cyclophosphamide toxicity (xlO).
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Discussion
We have already shown in chapter two that hDAF confers protection against HAR
when hDAF transgenic pig hearts are transplanted heterotopically into the abdomen of
non-immunosuppressed cynomolgus monkeys and that heterozygous hDAF transgenic
pig hearts had a median beating time of 5.1 days. The aim of this part of the study was
to determine the effect of a simple immunosuppressive regimen on prolongation of
survival of heterozygous hDAF transgenic pig hearts in cynomolgus monkeys. CyP
was chosen as the anti-B cell agent as prolonged survival of hamster-to-rat heart
xenografts has been demonstrated when CyP was combined with CyA.98
We have confirmed in this study that HAR can be abrogated with the hDAF transgene
in this discordant pig-to-primate model. Indeed of the fifteen transgenic pig heart
transplants performed none were hyperacutely rejected, whereas all five normal pig
hearts were rejected hyperacutely.
It has also been demonstrated that the high dose, group 1, immunosuppressive
regimen prolonged survival of xenografts out to 62 days (median survival 40 days).
This contrasted markedly with the control hearts, all of which were hyperacutely
rejected with a median beating time of 55 minutes. Only two hearts in the high CyP
group were rejected, on days 6 and 62: all other hearts showed no evidence of
rejection. Both rejected hearts demonstrated AVR histologically, but the heart which
was rejected on day 6 was shown histologically to express very little hDAF on it's
endothelium (1+). This was also the first cynomolgus recipient to be
immunosuppressed and it was clear that cynomolgus monkeys do not absorb CyA and
CyP with the same profile as humans. As a result inadequate doses of drugs were
administered to this recipient and the heart was rejected on day 6. Despite the apparent
efficacy of the group 1 regimen 40% of recipients were sacrificed with beating cardiac
xenografts due to intractable diarrhoea. This was thought to be a direct result of CyP
toxicity in cynomolgus monkeys. In an attempt to reduce the dose of CyP administered
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to the monkeys, and therefore the toxic side effects, and armed with in vitro evidence
suggesting that CyP may be more effective if given shortly after the immunological
stimulus,87 no perioperatve CyP was given to the group 2 monkeys. This resulted in a
44% reduction in the amount of CyP administered during the first nine days. None of
the recipients developed diarrhoea but all five cardiac xenografts underwent AVR with
a median survival of nine days.
Although the aim was to achieve a trough CyA level of 400ng/ml in both groups, and
although the mean CyA dose administered to each group was similar, the mean CyA
level achieved in the group 2 recipients was 876±291ng/ml compared with
554±70.7ng/ml in group 1. This difference didn't quite reach statistical significance
(p=0.07). This observation may be accounted for by the troublesome diarrhoea in
group 1 recipients perhaps interfering with CyA absorption and hence resulting in
lower blood levels of the drug for a given dose. Interestingly, despite the higher CyA
levels in group 2, it was the group 2 xenografts which were all rejected.
The immunosuppressive protocols chosen here could be applied clinically. The doses
of CyP and cyclosporin given to the monkeys when measured in mg/kg were certainly
large by clinical standards.87 However these doses had to be increased to these levels
to allow for the differences in absorption and metabolism of these drugs in
cynomolgus monkeys, so that drug levels and haematological responses similar to
those in current clinical practise could be achieved.
CyA was administered at doses necessary to achieve blood trough levels of 400ng/ml.
Abnormal renal function did not occur in any of these animals. CyP was administered
at doses necessary to achieve a total white count of 2xl06/ml. This threshold
represents the haematological criterion currently used in the treatment of autoimmune
diseases and is achieved with daily doses of 2-4mg/kg in man.87 However, our group
2 monkeys required three times this dose to reduce the wcc to a mean of 4.7xl06/ml in
the first nine days following transplantation. Intestinal complications associated with
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the group 1 regimen were responsible for the sacrifice of 50% of the
immunosuppressed monkeys with heart xenografts still beating. No infective cause
was isolated from stool cultures and histological examination demonstrated a non¬
specific ileitis/colitis consistent with CyP toxicity. Diarrhoea has been reported in 22%
of patients treated with CyP.89 Clearly in the clinical setting appropriate supportive
treatment would have been available.
Despite the reduction of the CyP dose administered to group 2 recipients the rate of fall
of all haematological parameters i.e. total wcc, lymphocyte count, neutrophil count,
haemoglobin concentration and platelet count was similar in both groups. The only
difference was that the fall in group 2 lagged behind the fall in group 1 as might be
expected when no perioperative CyP was given to group 2 recipients.
In all three groups the pretransplant natural APAb level in the cynomolgus monkey
started at a level which was in excess of a pool of ten human sera, which was
arbitrarily given a level (calculated from the area under the curve {AUC}) of 1000
units. Immediately following transplantation the APAb fell to almost zero, in both
groups 1 and 2, presumably due to immunoabsorption onto the xenograft.
In group 1 the elicited total APAb levels, in general, remained low until about the third
postoperative day, at which time they began to rise and peak by the fifth postoperative
day. Beyond the fifth postoperative day there were a variable number of peaks and
troughs of antibody levels. The amplitude of these peaks also varied widely. Despite
the many antibody peaks, however, only two resulted in xenograft rejection.
In contrast, the pattern of elicited total APAb levels and their effect on graft viability in
group 2 was markedly different. The levels initially remained low until about the fifth
to eighth postoperative days, at which time there was again an increase in antibody
levels in four out of five recipients, resulting in every case in xenograft rejection. The
only recipient in group 2 in which there wasn't an antibody increase around this time
was W544. In W544 the elicited total APAb level remained low until the 24th
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postoperative day at which time there was a small peak and a later increase in antibody
level on the 33rd postoperative day which resulted in xenograft rejection.
It appears that perioperative CyP in some way protected the grafts from later antibody
attack, or that there may be more than one type of APAb involved, such that recipients
in group 1 were able to tolerate such peaks of antibody whereas group 2 recipients
were not.
We have confirmed in this study that HAR can be abrogated with the hDAF transgene
in this discordant pig-to-primate model. Indeed, of the fifteen transgenic pig heart
transplants performed, none were hyperacutely rejected whereas all five normal pig
hearts were rejected hyperacutely. Two hearts in group 1 were rejected: all other hearts
showed no evidence of rejection. Both rejected hearts demonstrated AVR
histologically. All five group 2 cardiac xenografts underwent AVR.
A comparison of group 1 transgenic xenograft and control histology demonstrated no
evidence of inflammation, cell damage or infiltrate in the eight transgenic grafts which
were not rejected and while the control grafts were severely damaged. Those
histological parameters for which there was a highly significant difference at the level
p<0.001 were endocardial permeability and endocardial disruption. This suggests that
in this model, it was at the blood/endocardial interface where complement activation
and therefore hDAF had it's greatest effect.
There was heavy IgG, and C4 deposition in both groups but significantly more
(p<0.005) C3 and C9 deposition in the control grafts. This suggests that although
there was substantial antibody binding to the transgenic grafts the activation of the
terminal complement components was inhibited in the transgenic grafts. There was
also less activation of the coagulation cascade in the transgenic grafts, as indicated by
less VWF deposition (p<0.005) and less endothelial activation, revealed by staining
for P selectin (p<0.005).
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A comparison of group 2 transgenic xenograft and control histology demonstrated a
similar pattern to that observed between group 1 transgenics and the controls although
the degree of graft damage and histological changes in the group 2 xenografts was
florid (features of AVR) and so the statistical difference between group 2 and control
xenografts was less marked. Therefore, the amount of cellular infiltrate, myocyte
damage and congestion was the same in both group 2 transgenics and the controls.
Thus although the presence of hDAF on the pig endothelium was sufficient to protect
against HAR it was not able to protect against AVR in the presence of rising APAb
levels.
Again, there was heavy IgG and C4 deposition in both groups but significantly more
(p<0.05) C3 and C9 deposition in the control grafts. There was still, however,
substantial amounts of C3 (3+) and C9 (3+) deposited in the group 2 transgenic grafts.
This would again support the hypothesis that complement activation plays an important
part in the pathogenesis of AVR. Again, there was less activation of the coagulation
cascade in the transgenic grafts, as indicated by less VWF deposition (p<0.05). The
difference between group 2 transgenics and controls was however, statistically most
significant for P selectin (p<0.005) indicating again that the presence of hDAF protects
the pig hearts against endothelial cell activation.
A comparison of group 1 and group 2 transgenic xenograft histology demonstrated
significantly more haemorrhage, thrombosis, oedema and cellular infiltrate in the
group 2 xenografts. There was significantly more activation of the complement and
coagulation cascades and more CD-4 and CD-8 T cells in the group 2 xenografts.
In summary FIAR can be abrogated with the hDAF transgene in this pig-to-primate
model and prolonged survival can be achieved. Perioperative CyP would appear to be
an essential component of this regimen, without which, graft loss due to antibody-
mediated AVR is encountered. There is clearly a need for an effective anti-B cell agent,
with fewer gastrointestinal and haematological side effects, which can specifically
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target elicited anti-pig antibodies and so overcome the next hurdle on the way to
clinical pig-to-human heart transplantation. A number of potential agents now exist and
these are described in the following section.
Leflunomide, an isoxazole, interferes with lymphocyte interleukin-2 responsiveness
and has recently been shown to be a potent immunosuppressive agent.106'107
Brequinar sodium is an antipyrimidine compound which noncompetatively inhibits the
activity of the enzyme, dihydro-orotate dehydrogenase. Inhibition of the de novo
pyrimidine biosynthetic pathway results in the depletion of the nucleotide precursors
(uridine and cytidine) necessary for DNA and RNA synthesis. The dependence of
lymphocytes on the de novo pyrimidine pathway for synthesis of DNA and RNA
results in a high level of sensitivity to the action of brequinar during the proliferative
phases of an active immune response. In vitro and in vivo experimental studies have
confirmed the potent immunosuppressive characteristics of brequinar.108,109
Rapamycin, a potent immunosuppressive agent, has been demonstrated to have
remarkable activity in inhibiting allograft rejection in animal models of transplantation.
It belongs to the class of macrocyclic immunosuppressive drugs that are bioactive only
when bound to immunophilins. CyA and FK506 are also included in this class, but
rapamycin acts at a later stage in the T cell cycle progression by blocking cytokine-
mediated signal transduction pathways.110 Deoxyspergualin is effective in prolonging
the functional survival of allogeneic and xenogeneic grafts through ill-defined
mechanisms affecting macrophage and T and B cell function.111 Mycophenolate
mofetil is a new selective immunosuppressant used for the prevention and treatment of
acute renal rejection after transplantation.112 In vivo it is de-esterified to mycophenolic
acid, which is a potent and specific inhibitor of de novo purine synthesis and
suppressor of both T and B cell proliferation. Inhibition of vascular rejection in cardiac
xenografts of cynomolgus monkeys transplanted into baboons has been
demonstrated.113
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Finally, sustained suppression of xenoreactive natural antibodies with anti-IgM
monoclonal antibody114 has been demonstrated and monoclonal antibodies against
CD4 and CD8 T cells in mice has been shown to prolong rat heart xenograft
survival.115
As illustrated, there is an extensive armamentarium of new immunosuppressive agents
currently available. Therefore one would hope that it should be possible to improve on
the results which we have achieved in this study with a simple regimen of CyA, CyP
and steroids in combination with the hDAF transgenic pig heart.
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Chapter Four
Life supporting pig-to-baboon cardiac xenotransplantation
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Introduction
We have already demonstrated in chapter two that hearts from hDAF transgenic pigs
were not hyperacutely rejected when transplanted heterotopically into the abdomen of
cynomolgus monkeys (Macaca fasicularis). We have further demonstrated in chapter
three that prolonged survival of transgenic pig hearts was achieved when recipient
cynomolgus monkeys were immunosuppressed with Cyclosporin A (CyA),
Cyclophosphamide (CyP) and methylprednisolone (MP). The aim of the following
studies was to determine whether transgenic pig hearts were able to support the life of
a non-human primate.
In the earlier studies described in chapters two and three we chose the cynomolgus
monkey as the recipient of heterotopic hDAF transgenic pig hearts largely because of
the plentiful supply. However, such captive bred animals were rarely available with a
body weight of greater than five kilograms. Hence the cynomolgus monkey was an
unsuitable recipient for orthotopic heart transplantation due to the technical difficulties
associated with cardiopulmonary bypass in such small recipients. Therefore, it was
necessary to choose a larger primate for further studies. Many of the larger primates
are endangered species and it was deemed ethically unacceptable to use such animals
for this purpose. Of the larger primates readily available in sufficient numbers the
baboon was considered to be the most suitable recipient. However, it has been shown
that hDAF has a variable ability to down regulate complement of non-human primates
(Tucker A and White D: personal communication). Indeed, hDAF has been shown to
down regulate human complement activity by 84% of total plasma complement
activity, cynomolgus complement by 72%, baboon complement by 69% and rhesus
complement by 28%. Clearly the rhesus monkey would not be a good choice of
experimental recipient for hDAF transgenic organs. However, it was not clear whether
the 3% difference between the cynomolgus monkey and the baboon would be
sufficiently large enough to result in HAR in the pig-to-baboon model. It was therefore
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considered necessary to test hDAF in this model by transplanting hDAF transgenic pig
hearts heterotopically into the neck of the baboon prior to performing orthotopic pig-
to-baboon heart transplantation.
It has already been shown in a heterotopic pig-to-baboon model that complement
depletion with cobra venom factor results in the delay of hyperacute rejection and
that such grafts survived for up to 68 hours in this model without any other
form of immunosuppression.48 With a combination of CyP, 15-deoxyspergualin,
splenectomy, baboon specific polyclonal anti-lymphocyte globulin and plasmapheresis
survival of heterotopic pig hearts in baboons of 17 days has been achieved.63 Pig-to-
baboon functioning renal xenograft survival of up to 22 days has been achieved with a
similar immunosuppressive regimen.116
The combination of cobra venom factor, splenectomy, CyA, prednisolone, CyP and
methotrexate has resulted in pig-to-baboon heterotopic cardiac xenograft survival of 25
days.104
Prolonged survival of life-supporting orthotopic pig hearts in the baboon for up to 16
days has also been achieved117 by using a radical immunosuppressive approach based
on pretransplant splenectomy, recipient immunoabsorption and nafamstat mesilate. In
addition, CyA and deoxyspergualin were administered to these animals. Histological
investigations performed at the end of the study showed that even such a complex





Large white/Landrace cross-piglets of either sex were selected as donors on the basis
of degree of hDAF expression, as described in chapter two, and on the basis of their
body mass. All donors were heterozygous for hDAF.
Heterotopic cervical model (n=3)
2-3 kg piglets were used (i.e. as small as possible) because of the restricted space
within the baboon neck.
Orthotopic model (n=5)
5-6 kg piglets were used as these were found to have comparable size hearts to the
recipient baboons thus allowing anastomoses of vessels of similar sizes and allowing
the heart to sit within the pericardial space without being tamponaded.
Recipient selection
For both the heterotopic and orthotopic models wild-caught baboons (Papio anubis,
age 2-4 years, weight 6.8-9.3kg) as large as possible were used so that the technical
difficulties associated with these procedures were minimised.
Donor operation
Heterotopic cervical cardiac transplantation
This was as described for heterotopic abdominal cardiac transplantation in chapter two.
Orthotopic cardiac transplantation
After sedation with ketamine hydrochloride (20mg/kg) and oxygen mask induction, a
tracheostomy was performed and mechanical ventilation was begun. General
anaesthesia was maintained with N20:02 (1:1) and isoflurane (1-2%).
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A median sternotomy was performed, the pericardium was opened longitudinally, and
heparin (300 iu/kg) was given intravenously. The inferior vena cava (IVC) was tied
above the diaphragm, and incisions were made into the IVC and the left superior
pulmonary vein to decompress the heart. The aorta was then cross-clamped at the level
of the right brachiocephalic artery and St. Thomas's cardioplegic solution (15ml/kg)
was infused at a temperature of 4°C into the aortic root. The heart was excised after
division of the superior vena cava, IVC, pulmonary veins pulmonary artery and aorta.
The heart was kept cool by topical irrigation with cold normal saline at 4°C. Simple
defects such as a patent foramen ovale were repaired.
Recipient operation
Heterotopic cervical cardiac transplantation
All animals were starved overnight prior to surgery. Before transfer to the operating
theatre the baboon was sedated with ketamine hydrochloride (15mg/kg) given
intramuscularly in combination with atropine sulphate (0.05mg/kg).
Following induction of anaesthesia, by intravenous injection of diazepam (lmg/kg), an
endotracheal tube was inserted and the baboon was maintained on a N20:C>2 (1:1)
mixture, with the addition of isoflurane at a concentration of 1-2% as required and
propofol (50mg/kg). A single dose of a prophylactic antibiotic was given (Synulox).
Analgesia was achieved by intravenous fentanyl citrate. An indwelling cannula was
inserted into a peripheral vein for administration of fluids and drugs during the
procedure. Electrocardiographic and respiratory monitoring was established.
The skin over the right side of the baboon's neck was then prepared with antiseptic
solution and sterile drapes were applied to expose the operative field. An oblique neck
incision was performed which was taken down through platysma and a self-retaining
retractor was inserted. A 2-3cm long segment of internal jugular vein and internal
carotid artery was then exposed. Donor ascending aorta was anastomosed to the
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recipient internal carotid artery and the donor pulmonary artery was anastomosed to the
recipient internal jugular vein.119
100 iu of heparin was given intravenously and allowed to circulate for two minutes
prior to occluding the internal jugular vein and internal carotid artery using silastic
slings. With the heart wrapped in a cold saline-soaked swab, and kept cold at all times,
the anastomoses were performed using 7-0 prolene sutures (non-absorbable
monofilament) and standard microvascular surgical techniques. On completion of the
anastomoses the vessels were flushed with heparinised saline and all air was expelled.
After checking the anastomoses for any obvious surgical bleeding the slings were
carefully removed (the ischaemic time noted) and the surgical field was gently packed
with swabs. 20mls of haemaccel (plasma expander) was given intravenously. If the
heart did not spontaneously cardiovert a 2J DC shock was administered and repeated if
required. The swabs were then removed, the surgical field was carefully examined for
bleeding and thorough haemostasis was achieved. Finally, thrombin glue (Tisseal
glue, Immuno Ltd High Wycombe, UK) was applied around the anastomoses and the
heart was carefully positioned to avoid compromising the activity of the donor heart.
When we were satisfied that there was stable xenograft function and adequate
haemostasis the wound was closed with 3-0 vicryl sutures (absorbable) to close the
platysma and 3-0 subcuticular vicryl for the skin. The recipient was allowed to recover
from general anaesthesia in the most appropriate position for the graft and was
maintained in an incubator until sitting up, at which time it was returned to its cage.
Postoperative management
First hour
This period was critical. The animal was observed very closely during this period and
kept in the operating theatre with full anaesthetic and surgical facilities available,
should it have been necessary to reopen the cervical wound.
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Hours 2-24
Postoperative analgesia (buprenorphine hydrochloride, 0.3mg/ml) was administered at
the discretion of the attending veterinary surgeon.
During the first 24 hours the donor heart was checked every hour to confirm that it
was beating and if there was any problem with it, or with the animal, the surgeon was
notified.
Day 2 onwards
The general physical condition of the recipient and the xenograft function was checked
three times each day and any problem was reported to the on-call surgeon.
Orthotopic cardiac transplantation
Preoperative venesection
Cardiopulmonary bypass in very small animals is technically difficult.
Cardiopulmonary bypass circuit procedures can lead to marked haemodilution. Blood-
based prime reduces such effects. Human-type ABO blood grouping can easily be
performed in baboons, but without a readily available bank of typed baboon blood it is
of limited use. Simian-type blood grouping is more complex.70 In order to circumvent
these difficulties each recipient baboon was venesected (9mls/kg) on two separate
occasions each 28 days apart. The second venesection was 28 days prior to
transplantation. The blood was frozen at -35°C and stored at the National Blood
Service (Birmingham Centre, UK) and then defrosted on the day of transplantation.
By retransfusing the stored blood it was possible to avoid significant anaemia
following cardiopulmonary bypass.
Recipient operation
Through a median sternotomy the cardiectomy and orthotopic heart transplantation was
performed using the atrial cuff technique.120
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Meticulous surgical technique and haemostasis were essential. After implantation and
discontinuation of cardiopulmonary bypass the chest was closed leaving a single chest
drain in the pericardium.
Postoperative management
First hour
If significant bleeding did not occur within one hour, the drain was removed and the
animal was extubated, otherwise the chest was reopened immediately and the source of
the bleeding was identified and rectified.
Hours 2-24
Having completed the operation the animal was allowed to recover in an incubator and
subsequently transferred to an oxygen-enriched cage without intravenous fluid
replacement or inotropic support. Postoperative analgesia (buprenorphine
hydrochloride, 0.3mg/ml) was administered at the discretion of the attending
veterinary surgeon.
During the first 24 hours the baboon was checked every hour and if there was any
problem the surgeon was notified.
Day 2 onwards
The general physical condition of the baboon was checked three times each day and
any problem reported to the on-call surgeon.
Immunosuppression
Cyclosporin A
All animals in both groups received CyA to achieve trough levels in excess of 600
ng/ml. A target cyclosporin level as high as 1500ng/ml has been recommended to have




MP was commenced at lmg/kg/day reducing to 0.2mg/kg/day by day 18.
Cyclophosphamide
CyP was given intravenously on the preoperative day at 40mg/kg, the operative day at
20mg/kg, the second postoperative day at 10-40mg/kg and alternate days thereafter,
tailored to the white cell count (wcc) and the total haemolytic red blood cell anti-pig
antibody (APAb) levels. This immunosuppressive regimen was similar to that received
by the group 1, or high CyP, cynomolgus monkey recipients in chapter three. CyP
was administered to achieve a minimum total wcc of 2xl06/ml. This minimum wcc
reflects experience which has recently been gained in clinical immunosuppression of
patients suffering from autoimmune diseases such as systemic lupus erythematosus.87
Some authors even recommend a wcc as low as 1.5xl06/ml as the minimum acceptable
level for immunosuppression in patients with lupus nephritis.122 In two orthotopic
baboons the postoperative CyP was reduced, each baboon receiving a total of
lOmg/kg.
Blood sampling and monitoring
Blood was sampled regularly for full blood count and differential white cell count
(Bayer-Technicon haematology analyser), electrolytes and creatinine (Hitachi 737
clinical chemistry analyser) trough CyA levels (thin-layer chromatography, Papworth
Hospital), total red blood cell haemolytic anti-pig antibody (APAb) levels (as described
in chapter 2) and the immunosuppression was tailored accordingly.
Diagnosis of Xenograft Rejection
Heterotopic cervical model
Rejection of the heterotopic hearts was defined as the absence of palpable cardiac
pulsation confirmed by histological examination of the graft.
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Orthotopic model
Rejection of the orthotopic grafts was diagnosed by a rise in the total haemolytic red
blood cell APAb levels and/or by clinical signs of heart failure (weight increase,
oedema, dyspnoea and cardiac dysrhythmia) and confirmed by histological
examination of the grafts.
Histology
Donor
All donor ear clippings were scored for hDAF expression as described in chapter 2.
Only top-scoring hDAF transgenic organs were used.
Recipient
All explanted hearts were examined histologically with haematoxylin and eosin (H+E)
staining for each of the parameters as described in chapter two. All histological
parameters were graded on a scale of 0 to 4.
Immunohistology
Cardiac tissue was also snap-frozen in liquid nitrogen and stained for each of the
immunohistological parameters using mouse anti-human C3, C4, C9 and IgG
monoclonal antibodies (mAbs)(Dako Ltd, High Wycombe, UK) and IgM (mouse anti-
human mAb, Immunotech SA, Marseilles, France) by the avidin-biotin complex
method. Explanted grafts were evaluated for galactose a 1-3 galactose expression.
This was determined by measuring the intensity of biotinylated Griffoma (bandeirae)
Simplicifolia Lectin 1 binding (GSL: Vector, California, USA). Explanted grafts were
also stained for the adhesion molecule P selectin using a mouse anti-human mAb
against P selectin (Immunotech, Hamburg, Germany) and Von Willebrand's Factor
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(VWF) using mouse anti-human mAb against VWF (DAKO Ltd, High Wycombe,
UK). These parameters were measured semi-quantitatively on a scale of 0 to 4.
The cellular infiltrate was evaluated in each graft by counting the mean number of cells
per high power field (HPF). Tissue platelets were identified by mouse anti-human
mAb against P selectin (Immunotech, Hamburg, Germany) and neutrophils by mouse
anti-human neutrophil mAb. CD-4 T helper cells using mouse anti-human CD-4 mAb
(DAKO Ltd, High Wycombe, UK), CD-8 T cytotoxic cells using mouse anti-human
CD-8 mAb (DAKO Ltd, High Wycombe, UK), CD-19 B cells using mouse anti-
human CD-19 mAb (DAKO Ltd, High Wycombe, UK) and CD-68 macrophages
using mouse anti-human CD-68 mAb (DAKO Ltd, High Wycombe, UK).
Bone marrow examination




The results are summarised in table 4.1.
Recipient Survival Outcome
Heterotopic 1 13 days Acute vascular rejection
Heterotopic 2 2 days Sacrificed: cerebrovascular accident
Heterotopic 3 21 days Sacrificed: cervical abscess eroding internal jugular vein
Orthotopic 1 9 days Bone marrow suppression
Orthotopic 2 5 days Acute vascular rejection
Orthotopic 3 5 days Acute vascular rejection
Orthotopic 4 11 hours Technical failure: pulmonary artery thrombosis
Orthotopic 5 6 hours Technical failure: left ventricular infarction
Table 4.1. Summary of hDAF transgenic pig-to-baboon cardiac xenotransplantation.
Heterotopic hearts (n=3) None of the transgenic pig hearts were hyperacutely rejected.
One heart underwent AVR on day 13 in association with a rising total APAb (figure
4.3) and the remaining two recipients were sacrificed with beating xenografts, one on
day two, following a cerebrovascular accident, and one on day 21 due to a cervical
abscess eroding the internal jugular vein leading to haemorrhage and collapse of the
animal. In the latter two recipients there was no evidence of rejection.
Armed with the knowledge that the hDAF transgene is clearly able to abrogate HAR in
this pig-to-baboon heterotopic heart transplantation model we were able to proceed
onto the second phase of this experiment i.e. life-supporting hDAF transgenic pig-to-
baboon orthotopic heart transplantation.
Orthotopic hearts (n=5) None of the hearts were hyperacutely rejected. Two
xenografts failed due to technical reasons, one failed 11 hours after transplantation due
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to a kinked pulmonary artery anastomosis leading to right heart failure and thrombus
formation in the right atrium and ventricle. A second graft failed six hours after
transplantation due to dysrhythmia secondary to left ventricular infarction.
Two xenografts stopped beating on day five in the presence of rising total APAb
(figure 4.3) and histological examination demonstrated AVR. Of these two recipients,
the recipient of the third orthotopic baboon heart (orthotopic 3) underwent two
consecutive orthotopic heart transplantations during the same operation. The first graft
failed after 20 minutes and so a second hDAF transgenic pig heart was transplanted
which survived for five days.
Finally, one recipient was sacrificed on day nine with a life-supporting xenograft. At
the time of sacrifice this recipient was pancytopaenic with a haemoglobin of 8.8g/dl,
total white blood cell count of 0.15 xl06/ml and a platelet count of zero. This
haematological state lead to widespread petechial haemorrhage and poor general
condition. Bone marrow examination confirmed marrow suppression.
Surgical details of orthotopic heart transplantation
Recipients of orthotopic hearts 1 and 2 survived the procedure without any lasting
perioperative insult. However, the xenograft in orthotopic 3 failed after only 20
minutes without any obvious cause. The heart became engorged, mottled and purple.
It then developed a bradycardia and stopped beating. Therefore, a second donor pig
was rapidly prepared, the heart was harvested, and under the same anaesthetic, and
with the recipient baboon maintained on cardiopulmonary bypass, a second orthotopic
heart transplant was performed (hence the very long bypass time of 238 minutes for
this recipient). This xenograft went on to function well.
Technical difficulties were experienced with orthotopic 4. At the time of the operation















1 9 days Bone marrow suppression 59 40 55.3 1024
2 5 days Acute vascular rejection 70 64 39.4 967
3* 5 days Acute vascular rejection 238 53 30 1152/98
4 11 hours Pulmonary artery thrombosis 110 54 57.8 919
5 6 hours Primary graft failure 74 61 30.6 1133
3* = recipient received two transplants
CPBT = Cardiopulmonary bypass time, IT = Ischaemic time
APAb = Anti-pig antibody, AUC = Area under curve units
Table 4.2. Surgical details and preoperative antibody levels in orthotopic baboons.
This resulted in a very difficult pulmonary artery anastomosis and created a long
pulmonary artery which may have led to it kinking. The degree of difficulty of this
operation is also reflected in the relatively long cardiopulmonary bypass time of 110
minutes. This xenograft stopped beating 11 hours following transplantation and at the
time of the postmortem the pulmonary artery was found to contain thrombus proximal
to a kinked pulmonary artery. Histological examination demonstrated no evidence of
rejection.
Although the operation on orthotopic 5 was uncomplicated, on removing the aortic
cross clamp and allowing the xenograft to reperfuse, ventricular fibrillation and
supraventricular tachycardia (SVT) were problematic. This graft later failed at six
hours and histological examination suggested that this was due to ventricular
fibrillation secondary to left ventricular infarction.
On completion of the anastomoses and reperfusion of the grafts five of the six grafts
developed ventricular fibrillation requiring 2 Joules DC cardioversion. All were
successfully converted to either sinus rhythm or SVT. Amiodarone (5mg/kg) was
administered to treat SVT. Bradycardic episodes and low output states were treated
with a combination of lmmol boluses of calcium chloride and 0.1ml of 1:10,000




All heterotopic baboons received the same CyP regimen as group 1 cynomolgus
recipients in chapter three i.e. the high CyP regimen. The first orthotopic baboon,
however developed profound marrow suppression and so the CyP dose was reduced
in the following two recipients from a mean daily dose of 15mg/kg to lOmg/kg. As
with immunosuppressed cynomolgus recipients of pig hearts in chapter three the CyP
dose was tailored to the wee and the total haemolytic red blood cell APAb levels. CyP
was administered to achieve a minimum total wee of 2xl06/ml. The mean daily dose of
CyP administered in an attempt to achieve these goals in both heterotopic and
orthotopic baboons was ll.l±2.2mg/kg.
Cyclosporin A
An attempt was made to achieve trough levels in excess of 600ng/ml. The actual mean
CyA level achieved in the heterotopic and orthotopic baboons was 987±76ng/ml
during the experiment. This required a mean daily CyA dose of 177±13mg/kg.
Electrolytes and creatinine levels
Electrolyte and creatinine levels were normal in all recipients. Postoperative creatinine
levels ranged from 0.7-1.3mg/dl (normal range 0.5-1.5mg/dl).
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Total white cell count
We can see from figure 4.1 that the mean total wcc in baboons following
transplantation with hDAF transgenic pig hearts, when immunosuppressed with CyA,
CyP and steroids, initially rose from a mean pretransplant level of 11.6±2.1xl06/ml














4.1. Mean total white cell count in baboons.
This was similar to the response seen in cynomolgus monkeys in chapter 3 and was
likely to represent the inflammatory reaction to surgery and indeed was mirrored by a
rise in neutrophils. Following this initial rise there was a rapid fall in the mean total
wcc such that by the fourth postoperative day the mean total wcc had fallen below
2xl06/ml. Beyond the fourth postoperative day, although there were fluctuations in the




The mean lymphocyte count in baboons, following transplantation with hDAF
transgenic pig hearts, immunosuppressed with CyA, CyP and steroids can be seen in
figure 4.2. We can see that there was initially a rapid fall from the pretransplant level
of 5.6xl06/ml (normal range 2.48-11.24x106/ml) to a post-transplant level of lxl06/ml
on the first postoperative day.
Days Post Transplantation
Figure 4.2. Mean lymphocyte count in baboons.
Thereafter there were fluctuations in the mean lymphocyte count but there was a clear
downward trend until the fourteenth postoperative day, following which there was a
slight recovery of the lymphocyte count which followed a reduction in the CyP dose.
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Total anti-pig antibody levels
Figure 4.3 shows the pre and post-transplant total APAb levels in heterotopic and
orthotopic baboons surviving beyond the first post-transplant day. We can see from
figure 4.3 that the total APAb levels in both the heterotopic and orthotopic baboons
initially started at pretransplant levels of between 430 and 1152 units and immediately
following transplantation all fell to around zero (presumably due to immunoabsorption
onto the graft). Note that in orthotopic 3 the pretransplant total APAb level started at
1152 units and that the first pig heart grafted failed with no obvious cause identified.
During the same anaesthetic a second pig heart was transplanted successfully which















4 ■ Ortho 3
10 15
Days Post Transplantation
Figure 4.3. Total anti-pig antibody levels in heterotopic and orthotopic baboons.
Following the explant of the first transplanted heart, and prior to implantation of the
second heart, the total APAb level was found to be 98 units and therfore the second
graft may have been relatively protected against anti-pig antibodies by the initial
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perfusion of baboon blood through the first pig heart, thus facilitating
immunoabsorption of anti-pig antibodies onto the graft.
The other two orthotopic hearts which were thought to fail for technical reasons, i.e.
orthotopics 4 and 5, had pretransplant total APAb levels of 919 units and 1133 units
respectively (see table 4.2). So it would appear that there was no difference in the pre¬
transplant total APAb levels compared with those grafts that survived beyond the first
postoperative day. Histological analysis of these two grafts demonstrated no evidence
of rejection.
We can see from figure 4.3 that the elicited post-transplant total APAb level in
heterotopic 1 remained suppressed until the 12th postoperative day when it suddenly
started to climb and,despite an additional dose of CyP, the graft stopped beating on the
13th postoperative day, in the presence of a total APAb level of 971 units. Histological
examination of this graft demonstrated AVR. The elicited post-transplant total APAb
level in heterotopic 2 remained low and on the second postoperative day when the
baboon was sacrificed, having experienced a cerebrovascular accident, the total APAb
level was 56 units. Histological examination of this graft demonstrated no evidence of
rejection. The elicited post-transplant total APAb level in heterotopic 3 remained low
until the 20th postoperative day when there was a small increase in the level to 122
units. At this time an additional dose of CyP was administered but by the 21st
postoperative day it was clear that the baboon had developed a cervical abscess and so
it was sacrificed. At the time of sacrifice the total APAb level had fallen to 60 units and
histological examination of the xenograft demonstrated no evidence of rejection.
The elicited post-transplant total APAb level in orthotopic 1 remained suppressed
throughout its course but the animal was sacrificed with a beating life-supporting
cardiac xenograft on the ninth postoperative day due to poor general condition and
having developed widespread petechial bruising. At the time of sacrifice the total
APAb had risen to 177 units but histological examination of the xenograft
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demonstrated no evidence of rejection. In both orthotopics 2 and 3 the elicited total
APAb levels remained suppressed until the fifth postoperative day at which time the
xenografts stopped beating in the presence of rising total APAb antibody levels of 104
units and 718 units respectively. Histological examination of both xenografts
demonstrated AVR.
Histology
All transgenic donor hearts scored 4 (scale of 0 to 4) for hDAF expression.
The results of the grading for the histological parameters for heterotopic and orthotopic
xenografts can be seen in table 4.3.
Histological examination of the first heterotopic cardiac xenograft, which stopped
beating on day 13, demonstrated the typical features (although mild) of AVR i.e.
rupture of the endothelial cell layer, oedema, thrombosis, haemorrhage and focal
necrosis of the cardiomyocytes, with an infiltrate of both polymorphonuclear cells and
monocytes.
Xenografts from heterotopic recipients 2 and 3, which were sacrificed with beating
cardiac xenografts, demonstrated no evidence of rejection.
Histological examination of the first orthotopic cardiac xenograft which was sacrificed
on the ninth postoperative day, due to widespread petechial haemorrhage and poor
general condition, demonstrated no evidence of rejection (figure 4.4). Indeed normal
myocardial architecture was maintained and there was no cellular infiltrate.
The first cardiac xenograft {orthotopic 3(1)} transplanted into the third orthotopic
recipient failed after only 20 minutes without obvious cause and so a second cardiac
xenograft was implanted {orthotopic 3(2)} which stopped beating after five days.
Histological examination of orthotopic 3(1) demonstrated no evidence of rejection with
normal myocardial architecture and no cellular infiltrate. Histological examination of
orthotopic 3(2) demonstrated florid features of AVR as did orthotopic 2 i.e. rupture of
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the endothelial cell layer, oedema, thrombosis, haemorrhage and myocytolysis with a
predominantly lymphocytic infiltrate (figure 4.5).
Histological examination of both grafts which failed for technical reasons i.e.
orthotopics 4 and 5 demonstrated no evidence of HAR with no evidence of graft
thrombosis, endothelial cell rupture, endocardial damage or myocyte damage.
Examination of orthotopic 4 confirmed pulmonary artery thrombosis but no other
abnormality and examination of orthotopic 5 demonstrated a left ventricular infarction.
Immunohistology
The results of the grading for the immunohistological parameters and cell counts for
heterotopic and orthotopic xenografts can be seen in table 4.4.
Histological examination of the first heterotopic cardiac xenograft, which underwent
mild AVR on the 13th postoperative day, demonstrated heavy staining for IgG (4+).
There was moderate deposition of C3 (3+) and C4 (3+) and mild deposition of C9
(2+). There was a heavy deposition of VWF (4+) and mild staining for P selectin
(2+). The mean number of tissue platelets per high power field was nine and there was
a heavy cellular infiltrate of neutrophils (63/HPF), CD-68 macrophages (58/HPF),
CD-4 T helper cells (36/HPF) and CD-8 T cytotoxic cells (48/HPF). There was a
slight infiltrate of CD-19 B cells (4/HPF).
Xenografts from heterotopic recipients 2 and 3, however, which were sacrificed with
beating cardiac xenografts, demonstrated no evidence of rejection. Moderate staining
for IgG (3+) was present in both. There was equivocal deposition of C3 (1+), mild C4
(2+) and no C9 in both grafts. Mild deposition of VWF (2+) and no staining for P
selectin was seen in both grafts. The mean number of tissue platelets per high power
field in heterotopics 2 and 3 was three and five respectively. A mild cellular infiltrate of
neutrophils (10/HPF), CD-68 macrophages (18/HPF) and CD-8 cytotoxic T cells
(5/HPF) was seen in heterotopic 2 which survived for only two days. In contrast there
142
were no CD-4 T helper cells and no CD-19 B cells in the xenograft of heterotopic 2. In
heterotopic 3, which survived for 21 days there was a moderate cellular infiltration of
neutrophils (25/HPF) and CD-68 macrophages (28/HPF) and a mild infiltration of
CD-4 T helper cells (2/HPF). There were no CD-8 cytotoxic T cells or CD-19 B cells
in this xenograft.
Histological examination of the first orthotopic cardiac xenograft, which was sacrificed
on the ninth postoperative day due to widespread petechial haemorrhage and poor
general condition, demonstrated no evidence of rejection. There was moderate staining
for IgG (3+) and mild staining for IgM (2+). There was equivocal deposition (1+) of
C3, mild C4 (2+), no C9 (figure 4.6), mild deposition of VWF (2+) and no staining
for P selectin. Finally, there were no tissue platelets seen and there was no cellular
infiltrate.
Xenografts from orthotopic recipients 2 and 3(2), both stopped beating on day five
and histological examination demonstrated florid AVR in both. A moderate deposition
of IgG (3+) and a heavy deposition of IgM (4+) was present in both grafts. A heavy
(4+) deposition of C3, C4 and C9 (figure 4.6)was seen in both grafts. Both grafts also
had a heavy deposition of VWF (4+) and there was mild staining for P selectin (2+) in
orthotopic 2 and none in orthotopic 3(2). The mean number of tissue platelets per high
power field in orthotopics 2 and 3(2) was eight and 18 respectively. There was a
heavy infiltrate of CD-4 T helper cells, 14+42/HPF, CD-8 cytotoxic T cells,
10+59/HPF and CD-68 macrophages, 85+71/HPF. No CD-19 B cells were seen in
either graft.
Histological examination of orthotopic 3(1) which failed after 20 minutes without
obvious cause demonstrated no evidence of HAR. There was a heavy deposition of
IgG (4+) and IgM (3+), a mild deposition of C3 (2+), heavy deposition of C4 (4+)
and no C9. The deposition of VWF (2+) was mild and equivocal staining for P
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selectin (1+) was observed. There were no tissue platelets seen in the xenograft of
orthotopic 3(1).
Histological examination of both grafts which failed for technical reasons i.e.
orthotopics 4 and 5 demonstrated no evidence of HAR. These grafts demonstrated a
moderate deposition of IgG (3+) and heavy deposition of IgM (4+) anti-pig antibodies
(figure 4.7a). Deposition of C3 (2+) was mild, C4 (4+) heavy, while that of C9 (1+)
was equivocal in both (figure 4.7b). There was no staining for P selectin in either graft
and a mild deposition of VWF (2+) was seen in xenografts of orthotopic 4 and 5.
No tissue platelets were seen in either graft and no cellular infiltrate of any kind was
demonstrated in orthotopic 4. In orthotopic 5 there was no cellular infiltrate other than
a very mild infiltrate of CD-68 macrophages (2/HPF).
Bone marrow examination
Bone marrow from the first orthotopic recipient which was sacrificed on day nine,
having developed widespread petechial haemorrhages and a profound pancytopenia,
demonstrated marked bone marrow suppression with severely depleted
leukoerythroblastic precursors. Bone marrow from the two other orthotopic baboon
recipients which survived for five days (i.e. orthotopics 2 and 3) demonstrated no
evidence ofmarrow suppression with a normal leukoerythroblastic picture.
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Recipient Het 1 Het 2 Het 3 Orth 1 Orth 2 Orth 3(1) Orth 3(2) Orth 4 Orth 5
Outcome 13 d 2d 21 d 9 d 5 d 20 m 5 d 11 h 6 h
Retracted Endothelial Cells 2 0 0 0 4 0 4 0 0
Wbc Adherence 2 0 0 0 4 0 4 0 0
Endothelial Permeability 2 0 0 0 4 0 4 0 0
Endothelial Rupture 1 0 0 0 1 0 3 0 0
Vasculitis 1 0 0 0 4 0 3 0 0
Congestion 3 2 1 1 4 0 4 0 4
Thrombosis 2 0 0 0 4 0 4 0 0
Platelet Thrombi 1 0 0 0 4 0 3 0 0
Fibrin 4 1 2 1 4 0 4 0 2
Inflammatory Cells 2 0 0 0 4 0 3 0 0
Myocyte Damage 2 0 0 0 4 0 4 0 0
Mvocvtolvsis 0 0 0 0 4 0 4 0 0
Focal Necrosis 1 0 0 0 2 0 3 0 0
Diffuse Necrosis 0 0 0 0 0 0 3 0 0
Perivascular Infiltrate 2 0 0 0 4 0 0 0 0
Focal Infiltrate 2 0 0 0 0 0 0 0 0
Diffuse Infiltrate 0 0 0 0 0 0 3 0 0
Aggressive Infiltrate 0 0 0 0 2 0 3 0 0
Focal Haemorrhage 2 2 1 0 3 1 4 0 3
Diffuse Haemorrhage 0 2 0 0 2 0 3 0 1
Oedema 3 2 2 0 2 1 3 0 1
Endocardial Adherence 0 0 0 0 0 0 2 0 0
Endocardial Permeability 0 0 0 0 0 0 2 0 0
Endocardial Disruption 0 0 0 0 0 0 0 0 0
Hyperacute Rejection No No No No No No No No No
Acute Vascular Reiection Yes No No No Yes No Yes No No
No Evidence of Reiection No Yes Yes Yes No Yes No Yes Yes
Table 4.3. Histological grading and outcome for heterotopic and orthotopic baboons.
All histological parameters were graded according to intensity of staining on a scale
of 0 to 4. Het=heterotopic, Orth=orthotopic, m=minutes, h=hours, d=days.
Note none of the grafts hyperacutely rejected. Orthotopic graft 1, which supported
the life of a baboon for nine days, demonstrated no structural damage or cellular
infiltrate. However heterotopic graft 1 and orthotopic grafts 2 and 3 (2) showed
significant graft damage due to acute vascular rejection.
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Recipient Het 1 Het 2 Het 3 Orth 1 Orth 2 Orth 3(1) Orth 3(2) Orth 4 Orth 5
Outcome 13 d 2d 21 d 9 d 5 d 20 m 5 d 11 h 6 h
C3 3 1 1 1 4 2 4 2 2
C4 3 2 2 2 4 4 4 4 4
C9 2 0 0 0 4 0 4 1 1
IgG 4 3 3 3 3 4 3 3 3
IgM _ _ _ 2 4 3 4 4 4
P selectin 2 0 0 0 2 _ 0 0 0
Von Willebrand's Factor 4 2 2 2 4 _ _ 2 _
GSL.l 4 3 3 _ _ _ _ _
Mean number of cells /HPF
Tissue Platelets 9 3 5 0 8 _ 18 0 0
Tissue Neutrophils 63 10 25 _ _ _ _ _ _
CD-4 T Cells 36 0 2 0 14 _ 42 0 0
CD-8 T Cells _ 5 0 0 10 _ 59 0 0
CD-68 Monocytes 58 18 28 0 85 _ 71 0 2
CD-19 B Cells 4 0 0 0 0 _ 0 0 0
Hyperacute Rejection No No No No No No No No No
Acute Vascular Rejection Yes No No No Yes No Yes No No
No Evidence of Rejection No Yes Yes Yes No Yes No Yes Yes
Table 4.4. Immunohistological grading and outcome for heterotopic and
orthotopic baboons. All histological parameters were graded according to
intensity of staining on a scale of 0 to 4 or counted as mean number of cells / HPF
(high power field).
Het=heterotopic, Orth=orthotopic, m=minutes, h=hours, d=days.
HAR=Hyperacute rejection, AVR=Acute vascular rejection, NER=No evidence
of rejection.
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Figure 4.4. Section of cardiac tissue, stained with haematoxylin and eosin, from an
hDAF traasgenic pig heart transplanted orthotopically into an immunosuppressed
baboon demoastrating no evidence of rejection after nine days (x20).
Figure 4.5. Section of cardiac tissue, stained with haematoxylin and eosin, from an
hDAF transgenic pig heart transplanted orthotopically into an immunosuppressed
baboon demoastrating acute vascular rejection after five days (x20).
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Recipient W211 surviving for five days showing heavy C9 deposition in
association with acute vascular rejection (xlO).
Figure 4.6. Sectioas of cardiac tissue, stained for complement component C9,
from an hDAF traasgenic pig heart transplanted orthotopically into an
immunosuppressed baboon.
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(a) Cardiac tissue stained forlgG (xlO).
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(b) Cardiac tissue stained for complement component C9 (xlO).
Figure 4.7. Sections of cardiac tissue from an hDAF transgenic pig heart
transplanted orthotopically into an immunosuppressed baboon to show IgG
binding to graft without C9 activation.
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Discussion
It is clear from these results that HAR is abrogated in pig-to-baboon cardiac
xenotransplantation with the use of hDAF transgenic pigs and that hearts from these
pigs are able to support the lives of primates for a prolonged period. With a
combination of hDAF transgenic pig hearts and an immunosuppressive regimen of
CyA, CyP and steroids the abrogation of HAR and survival of heterotopic pig-to-
baboon heart xenografts for up to 21 days has been achieved. The hDAF transgenic
pig heart can support the life of a primate for up to nine days when immunosuppressed
with CyA, CyP and steroids and no other immune modulating strategies. Histological
analysis of this graft showed normal myocardial architecture with no evidence of
rejection.
Both the heterotopic and orthotopic pig-to-baboon heart transplantation models are
technically very demanding and technical failures are unfortunately inevitable. Despite
meticulous attention to surgical technique orthotopics 4 and 5 failed for what was
thought to be technical reasons after eleven and six hours respectively. Orthotopic 3
underwent two consecutive transplants as the first xenograft 3(1) failed after only 20
minutes. No cause was found for the failure of orthotopic 3(1) and there was no
evidence of rejection. The ischaemic time for this graft was, however, prolonged at 80
minutes and ischaemic injury may have resulted in early graft loss. Orthotopic 4 failed
due to pulmonary artery thrombosis secondary to kinking of the pulmonary artery, as a
direct result of the donor heart being too large (+57.8%). No other difference was
recorded compared with those grafts which were technically successful. There was no
significant difference in ischaemic time, cardiopulmonary bypass time or pretransplant
total APAb level (table 4.2). In every orthotopic transplantation the donor pig heart
was larger than the recipient baboon heart with a weight mismatch ranging from +5%
to +57.8%, despite the body weight of the donor pig being less than that of the
recipient baboon in every case. Experience obtained in this study indicated that the
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heart/body weight ratio of pigs is greater than that of baboons. Therefore, to match pig
and baboon heart sizes, and so make the operation technically less difficult, the body
weight of donor piglets should be 20-30% less than the recipient baboon weight.
Orthotopic 5 died of graft failure due to dysrhythmia following left ventricular
infarction and subsequent systemic acidosis six hours following surgery. The limited
postoperative care of the recipients without electrocardiogram, blood pressure and
central venous pressure monitoring made it difficult to determine the exact cause of the
early graft failure. It should be noted that there was a +30.6% weight mismatch in this
recipient and no difference in the cardiopulmonary bypass time, ischaemic time or
pretransplant total APAb compared with those technically successful orthotopic grafts.
In chapter three we found that although the high CyP regimen received by the group 1
cynomolgus recipients resulted in more side effects, the xenograft survival was
significantly greater than in the low CyP, group 2, recipients all of which underwent
AVR. The group 1 CyP regimen was therefore chosen for the immunosuppression of
the baboons. CyP was given intravenously on the preoperative day at 40mg/kg, the
operative day at 20mg/kg, the second postoperative day at 10-40mg/kg and alternate
days thereafter, tailored to the white count and the total haemolytic red blood cell
APAb levels. CyP was administered to achieve a minimum total wcc of 2xl06/ml. This
minimum wcc reflects experience which has recently been gained in clinical
immunosuppression of patients suffering from autoimmune diseases such as systemic
lupus erythematosus.87 Some authors even recommend a wcc as low as 1.5xl06/ml as
the minimum acceptable level for immunosuppression in patients with lupus
nephritis.122 The first orthotopic baboon, however, developed bone marrow
suppression and so the CyP dose in the other two successful orthotopic baboons was
reduced, each baboon receiving a total of lOmg/kg. The mean daily dose of CyP
received by all baboons was ll.l±2mg/kg. This compared with a mean daily dose of
17.9±3.6mg/kg in group 1 cynomolgus monkeys in chapter three. Clearly baboons
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either absorb CyP better than cynomolgus monkeys or their bone marrow
leukoerythroblastic precursors are more sensitive to it. It is noteworthy that the
baboons, unlike the group 1 cynomolgus monkeys, did not develop diarrhoea and this
might explain the smaller doses of CyP required to achieve the set criteria. It would,
however, still appear that baboon bone marrow is more sensitive to CyP than
cynomolgus monkey bone marrow as the total wee in the baboons had fallen by the
fourth postoperative day to below the set threshold level of 2xl06/ml and failed to
recover despite the reduction in CyP dose (figure 4.1). In cynomolgus monkeys by
careful manipulation of the CyP dose we were able to maintain the total wee at about
the threshold level. A similar pattern was also seen with the lymphocyte count in
baboons.
Data exists to suggest that CyA trough levels in baboons should be as high as
1500ng/ml121 and in these baboon models we aimed for trough levels in excess of
600ng/ml. The actual mean CyA level achieved in the baboons was 987±76ng/ml.
This required a mean daily dose of 177±12.7mg/kg. This compared with group 1
cynomolgus monkeys in chapter three in which we achieved a mean CyA level of
544±71ng/ml with a mean daily dose of 122±19mg/kg. This represented similar CyA
dosing in both cynomolgus monkey and baboon to achieve a given CyA trough level.
The pretransplant APAb levels in the baboons ranged from 430 units to 1152 units and
in each case fell almost to zero immediately following transplantation, presumably due
to immunoabsorption onto the graft. It should be noted that in orthotopic 3 the pre
transplant total APAb level started at 1152 units and that the first pig heart grafted
failed with no obvious cause identified. During the same anaesthetic a second pig
heart was transplanted successfully which went on to support the life of the recipient
baboon for five days. Following the explant of the first transplanted heart and prior to
implantation of the second heart the total APAb level was found to be 98 units and as
such the second graft may have been relatively protected against anti-pig antibodies by
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the initial perfusion of baboon blood through the first pig heart thus facilitating
immunoabsorption of anti-pig antibodies onto the graft.
There was a large variation in the elicited APAb level from one baboon to the next. Not
only did the elicited APAb level vary widely but the effect of a given antibody level on
the graft also varied. However, in every case where the graft was lost due to rejection
it was preceded by a rise in total APAb level to a variable degree. Heterotopic 1 was
rejected on the 13th postoperative day in the presence of a total APAb level of 971
units, while orthotopic 2 was rejected in the presence of a total APAb level of only 104
units (risen from 9 units the previous day). This would suggest that in this model the
development ofAVR is an antibody mediated phenomenon and it is likely that there is
more than one antibody, with different affinities, involved. We have already shown in
chapter two that in the non-immunosuppressed cynomolgus recipient of a pig heart
delayed xenograft rejection or AVR was preceded by a rise in total APAb level which
was mirrored by a rising anti-gal a 1-3 gal IgM level (see chapter two).
Histological examination of the first orthotopic xenograft which was sacrificed with a
beating life supporting cardiac xenograft on the ninth postoperative day demonstrated
no evidence of rejection and indeed normal myocardial architecture was maintained and
there was no cellular infiltrate. However, histological examination of bone marrow
from this animal demonstrated profound marrow suppression with grossly depleted
leukoerythroblastic precursors.
Those heterotopic and orthotopic grafts which were rejected demonstrated a
histological pattern first described in a discordant rodent model of complement-
depleted recipients and referred to as either AVR,81 or delayed xenograft rejection.123 A
cellular infiltrate consisting predominantly of macrophages (CD-68) and neutrophils
was found. CD-4 T-helper and CD-8 T-cytotoxic cells were also present in smaller
numbers.
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Marked C4 deposition was seen in all grafts but C9 was only detected (other than 1+)
in those three grafts which were rejected which suggests that terminal complement
pathway activation contributed to graft rejection. It is possible that insufficient
immunosuppression allowed the formation of high affinity induced anti-xenograft
antibodies which overwhelmed the complement inhibiting properties of hDAF.
Although the measurement of haemolytic anti-pig antibodies in the serum does not
accurately reflect what is happening at the level of the xenograft, the antibody peaks
that were observed in these animals at the time of rejection would support this. It
would appear that activation of terminal complement components via the classical
pathway plays an important role in the pathogenesis of AVR and that hDAF has a
limited ability in preventing this.
In those grafts which were rejected there was clear evidence of activation of the
clotting cascade with VWF deposition. In all grafts there was little P selectin staining,
reaching only as high as grade 2+ in those grafts which were rejected. This confirms
our findings in chapter two which suggested that hDAF, in addition to protecting
against HAR, also suppresses endothelial cell activation.
Histological examination of those grafts which failed for technical reasons at six and
eleven hours following surgery, interestingly, showed strong IgG and IgM binding to
the grafts, moderate C3, very heavy deposition of C4 and only slight deposition of C9
confirming that there was substantial antibody binding to the graft but that this did not
result in the activation of the terminal component of the complement cascade, as would
be expected from the point of action of DAF (see chapter 1). It is clear from these
results that HAR is abrogated in pig-to-baboon cardiac xenotransplantation with the
use of hDAF transgenic pigs and that hearts from these pigs are able to support the
lives of primates for a prolonged period. We have, however, also seen that CyP when
administered at a mean daily dose of 15mg/kg was associated with toxicity and bone
marrow suppression and that if this mean daily dose was reduced to lOmg/kg an
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elicited APAb response occurred around day five which resulted in loss of the graft
due to AVR. The large doses of CyA and CyP administered in these studies, compared
with doses employed clinically, were necessary to produce the desired serum CyA
levels and suppression of recipient white cells. Such dosing was thought to be
necessary due to the relatively poor absorption of these agents in non-human primates.
We anticipate that with the advent of new immunosuppressive agents specifically
targeting this antibody response, improved survival of hDAF transgenic pig organs in
primates will be achieved and that clinical xenotransplantation with hDAF transgenic





Heterotopic abdominal heart transplantation from neonatal pig-to-cynomolgus
monkey, heterotopic cervical heart transplantation from neonatal pig-to-baboon and
orthotopic heart transplantation from neonatal pig-to-baboon are exacting surgical
techniques associated with a significant technical failure rate. Despite this, we have
demonstrated that none of the hDAF transgenic grafts were hyperacutely rejected and
clearly hDAF protects pig cardiac xenografts from hyperacute rejection in cynomolgus
monkey and baboon. However, hyperacute rejection in the discordant pig-to-
cynomolgus monkey xenotransplantation model is not inevitable. Indeed only half of
the non-immunosuppressed control grafts were hyperacutely rejected with a median
beating time of 58 minutes and half underwent acute vascular rejection with a median
beating time of 3.25 days. Those non-immunosuppressed control hearts which were
not hyperacutely rejected were found to have significantly less GSL. 1 binding, and
hence glycosylated sugars, on the endothelium of their grafts. It is this finding i.e. the
relative lack of antigenicity in this group, which may help to explain why these control
animals survived far in excess of what was expected.
All cynomolgus monkey and baboon recipients had a high preformed natural anti-pig
antibody (APAb) level prior to transplantation which fell almost to zero immediately
following transplantation and which we believe was due to immunoabsorption onto the
graft. In support of this conclusion, there was a substantial amount of IgG bound to
those transgenic and control technical failure grafts (failing within a few hours of
transplantation) in both the cynomolgus monkeys and baboons and a substantial
amount of IgM bound to the technical failure grafts in the baboons. The fall in the total
APAb level immediately following transplantation was mirrored by a fall in
anti-galactose a 1-3 galactose (AAG) IgM but not IgG antibodies in the non-
immunosuppressed cynomolgus monkey and therefore it would appear that it was the
immunoabsorption of AAG IgM onto the graft which was the trigger for complement
activation and hyperacute rejection.
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The elicited total APAb level in the non-immunosuppressed cynomolgus monkeys
remained low until about the third postoperative day when it started to rise rapidly
resulting in graft loss in all cases by the fifth postoperative day. Graft loss in all cases
was due to acute vascular rejection (AVR). The hDAF transgenic grafts were able to
tolerate higher levels of elicited total APAb compared with the long-surviving controls
before succumbing to AVR. Clearly, hDAF conferred on the graft some degree of
protection against antibody mediated AVR. In the group 1, high dose
cyclophosphamide, immunosuppressed cynomolgus monkeys the elicited total APAb
levels remained low until about the third postoperative day, at which time they began
to rise and then tended to peak by the fifth postoperative day. Beyond the fifth
postoperative day there were a variable number of peaks and troughs of antibody
levels. The amplitude of these peaks also varied widely. Despite the many antibody
peaks, however, only two resulted in xenograft rejection. In contrast, the pattern of
elicited total APAb levels and their effect on graft viability in the group 2, low dose
cyclophosphamide, cynomolgus monkeys was markedly different. The levels initially
remained low until about the fifth to eighth postoperative days, at which time there was
again an increase in antibody levels in four out of five recipients, resulting in every
case in AVR. There was only one recipient in group 2 in which there wasn't an
antibody increase around this time, but a later peak in antibody level resulted in AVR
of the graft. It would appear that perioperative cyclophosphamide in some way
protected the grafts from later antibody attack, or that there may have been more than
one type of APAb involved such that recipients in group 1 were able to tolerate such
peaks of antibody whereas group 2 recipients were not.
In the baboon models there was a large variation in the elicited APAb level from one
baboon to the next. Not only did the elicited APAb level vary widely but the effect of a
given antibody level on the graft also varied. However, in every case where the graft
was lost due to rejection it was preceded by a rise in total APAb level to a variable
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degree. These results would suggest that the development of AVR is, at least in part,
an antibody mediated phenomenon and it is likely that there is more than one antibody,
with different affinities, involved.
In non-immunosuppressed cynomolgus recipients of pig hearts AVR was preceded by
a rise in total APAb level which was mirrored by a rising AAG IgM level and not by
the AAG IgG level. This suggests that, at least in the non-immunosuppressed
cynomolgus monkey, it was AAG IgM which was in part responsible for the
development of AVR.
We have shown that prolonged survival of heterotopic hDAF transgenic pig hearts can
be achieved both in the pig-to-cynomolgus monkey and in the pig-to-baboon models
with a simple immunosuppressive regimen of cyclophosphamide, cyclosporin A and
steroids. However, it would appear that cynomolgus monkeys do not absorb
cyclosporin A and cyclophosphamide as well as humans and so the doses of these
drugs had to be increased to levels which, by clinical standards, were high, but which
resulted in satisfactory cyclosporin A levels and haematological responses similar to
those seen in clinical practise. Such large doses of immunosuppressive agents were
not without their side effects. Indeed, 40% of cynomolgus recipients treated with the
group 1, high dose cyclophosphamide, regimen were sacrificed because of the
development of intractable diarrhoea, thought to be due to cyclophosphamide toxicity.
The omission of perioperative cyclophosphamide in the group 2, low dose
cyclophosphamide, immunosuppressed cynomolgus monkeys resulted in a 44%
reduction in the amount of cyclophosphamide administered, and although none of the
monkeys developed diarrhoea, all cardiac xenografts were lost due to AVR and so it
would appear that perioperative cyclophosphamide was an essential component of this
regimen. In the baboon model it would appear that baboons either absorb
cyclophosphamide better than cynomolgus monkeys or baboon bone marrow is more
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sensitive to it as smaller doses of cyclophosphamide were needed in baboons than in
cynomolgus monkeys to achieve the same degree of immunosuppression.
We have also shown that the hDAF transgenic pig heart is able to support the life of a
baboon, immunosuppressed with cyclosporin A, cyclophosphamide and steroids, for
a prolonged period.
Histological analysis of all xenografts has demonstrated that hDAF protects transgenic
pig hearts from damage from terminal components of the complement cascade.
Immunohistological analysis of all control hearts, compared with transgenic hearts,
demonstrated no difference in the amount of endothelial C4 deposition but significantly
more endothelial C3 and C9 deposition in the control grafts. This pattern is exactly as
would be predicted from the mode of action of DAF since this complement regulator
acts at the point of formation of the C3 convertases C4b2a and C3bBb. Histological
examination of those hDAF transgenic grafts which were lost due to AVR in both the
cynomolgus monkey and baboon models demonstrated heavy deposition of C3 and C9
in the grafts supporting the hypothesis that complement activation is not only
responsible for hyperacute rejection but also plays an important part in the
pathogenesis of AVR.
It would also appear that hDAF protects transgenic pig hearts from endothelial cell
activation as indicated by significantly less staining for the adhesion molecule P
selectin in the grafts of immunosuppressed cynomolgus monkeys and in the technical
failure transgenic grafts of non-immunosuppressed cynomolgus monkeys. And,
indeed, hDAF also protects transgenic pig hearts from damage from activation of the
coagulation cascade as indicated by significantly less fibrin deposition in the transgenic
technical failure grafts of non-immunosuppressed cynomolgus monkeys and
significantly less Von Willebrand's Factor deposition in transgenic grafts of
immunosuppressed cynomolgus monkeys.
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In all models described, those cardiac xenografts which were not either hyperacutely
rejected or whose recipients were not sacrificed for humane reasons were lost due to
AVR and in every case there was a cellular infiltrate consisting predominantly of
macrophages (CD-68) and neutrophils. CD-4 T-helper and CD-8 T-cytotoxic
lymphocytes were also present in smaller numbers. With appropriate
immunosuppression this infiltrate could be prevented in both the cynomolgus and
baboon models.
Finally, it is clear from these results that
a) hyperacute rejection can be abrogated in the pig-to-cynomolgus monkey and pig-to-
baboon models with the use of hearts transgenic for hDAF
b) prolonged survival can be achieved in these models with appropriate
immunosuppression and
c) hDAF transgenic pig hearts can support the life of a non-human primate for a
prolonged period.
However, it is also clear that antibody mediated acute vascular rejection poses the next
major hurdle to pig-to-primate xenotransplantation.
Future developments
The combination of further human regulators of complement activation with hDAF, for
example CD59, might be able to prevent antibody mediated acute vascular rejection.
Already human CD59 and hDAF transgenic pigs have been developed.
The additional use of immunoabsorbent columns for the removal of both preformed
naturally occurring and elicited anti-pig antibodies may also be useful in preventing
antibody mediated xenograft rejection. In particular, immunoabsorbent columns for the
removal of galactose a 1-3 galactose IgG and IgM are likely to be effective.
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In vivo infusion of soluble galactose a 1-3 galactose may also be of help in
overcoming the fierce anti-gal antibody response to the xenograft by neutralising
circulating anti-xenograft antibodies.
And finally, we anticipate that with the advent of new immunosuppressive agents (e.g.
leflunomide, brequinar, rapamycin, deoxyspergualin and mycophenolate mofetil)
specifically targeting this antibody response, improved survival of hDAF transgenic
pig organs in primates will be achieved and that clinical xenotransplantation with
hDAF transgenic pig organs might be possible.
Since the experimental work presented in this thesis was completed our knowledge of
xenotransplantation has grown.
Numerous approaches have been reported for removing preformed natural
antibodies.124 However, all such approaches result only in a transient fall in antibody
level and a later rebound to levels above the baseline. Therefore more recent efforts to
deplete the recipient's natural antibodies have begun to concentrate on attempts to
deplete the B-l population of B cells entirely or to induce tolerance in this population
for the gal a 1-3 gal determinant.125
Since expression of the gal a 1-3 gal determinant depends on the expression of the
galactosyl transferase enzyme, one approach to removing this determinant has been to
eliminate the galactosyl transferase gene by homologous recombination. Knock-out
mice lacking this gene have been produced.126 The technology for this approach is not
yet available in other species.
Cellular immune responses to xenografts are considerably stronger than comparable
responses to allografts. It is unlikely that currently available immunosuppressive
agents will either be potent enough or specific enough to suppress the xenogeneic
response in discordant xenotransplantation. For this reason, the success of clinical
xenotransplantation is likely to depend, at least in part, on finding ways of inducing
specific hyporesponsiveness, or tolerance, across xenogeneic barriers rather than
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relying entirely on non-specific immunosuppressive agents. However, the only
reported approach toward induction of specific tolerance for the clinically relevant pig-
to-primate species combination involves attempts to induce mixed chimerism through
bone marrow transplantation.127
These results suggest that combined approaches to control both the humoral and
cellular xenograft responses may eventually permit long-term acceptance of discordant
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